



JOINT TRIAL EXHIBIT LIST

Government          Plaintiff   X   Defendant   X   Joint          Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-1853					DRE 802 - Hearsay	00/00/2007 Drug-Drug Interactions Associated with Second-Generation Antipsychotics: Considerations for Clinicians and Patients
P-1854					DRE 802 - Hearsay	00/00/2007 Atypical Antipsychotics and Pituitary Neoplasms in the WHO Database
P-1855					DRE 802 - Hearsay	00/00/2001 "Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine" by Arfizzone, T
P-1856					DRE 802 - Hearsay	RESERVED
P-1857					DRE 802 - Hearsay	00/00/2002 "Abnormalities in Glucose Regulation During Antipsychotic Treatment of Schizophrenia" by Newcomer, J
P-1858					DRE 802 - Hearsay	00/00/2003 "Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment" by Melkersson, K
P-1859					DRE 802 - Hearsay	00/00/2000 "Elevated Levels of Insulin, Leptin, and Blood Lipids in Olanzapine-Treated Patients With Schizophrenia or Related Psychoses" by Melkersson, K
P-1860					DRE 802 - Hearsay	00/00/2004 "Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro" by Melkersson, K
P-1861					DRE 802 - Hearsay	00/00/2004 "Adverse Metabolic Effects Associated with Atypical Antipsychotics" by Melkersson, K
P-1862					DRE 802 - Hearsay	00/00/2007 "The CATIE Schizophrenia Trial: Results, Impact, Controversy" by Manschreck, T
P-1863					DRE 802 - Hearsay	00/00/2004 "Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications" by Leslie, D (J-16)
P-1864					DRE 802 - Hearsay	00/00/2006 "Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia" by Lambert, B
P-1865					DRE 802 - Hearsay	00/00/2002 "Olanzapine-Associated Diabetes Mellitus" by Koller, E
P-1866					DRE 802 - Hearsay	00/00/2001 "Clozapine-associated Diabetes" by Koller, E



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-1867					DRE 802 - Hearsay	00/00/1965 "The Environment and Disease: Association or Causation?" by Hill, A
P-1868					DRE 802 - Hearsay	00/00/2007 "Risk of Diabetes Mellitus Associated with Atypical Antipsychotic Use Among Medicaid Patients with Bipolar Disorder: A Nested Case-Control Study" by Guo, J
P-1869					DRE 802 - Hearsay	00/00/2006 "Risk of Diabetes Mellitus Associated With Atypical Antipsychotic Use Among Patients With Bipolar Disorder: A Retrospective, Population-Based, Case-Control Study" by Guo, J
P-1870					DRE 802 - Hearsay	00/00/2002 "Weight Gain Associated With Increased Food Intake and Low Habitual Activity Levels in Male Adolescent Schizophrenic Inpatients Treated With Olanzapine" by Gotthelf, D
P-1871					DRE 802 - Hearsay	00/00/2004 "Retrospective Cohort Study of Diabetes Mellitus and Antipsychotic Treatment in a Geriatric Population in the United States" by Feldman, P
P-1872					DRE 802 - Hearsay	00/00/2003 "Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study" by Bobes, J (J-8)
P-1873	Nasrallah 17				DRE 802 - Hearsay	00/00/2004 "Relationship Between Antipsychotic Medication Treatment and New Cases of Diabetes Among Psychiatric Inpatients" by Citrome, J.
P-1874					DRE 802 - Hearsay	00/00/2000 "The long-term effect of quetiapine (Seroquel) monotherapy on weight in patients with schizophrenia" by Brecher, M
P-1875					DRE 802 - Hearsay	00/00/1997 "Multiple Fixed Doses of Seroquel (Quetiapine) in Patients with Acute Exacerbation of Schizophrenia: A Comparison with Haloperidol and Placebo" by Arvanitis, L.
P-1876					DRE 802 - Hearsay	00/00/2000 "A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, Seroquel) and haloperidol in schizophrenia" by Copolov, D (J-12)
P-1877					DRE 802 - Hearsay	00/00/1999 "Antipsychotic Drugs Affect Glucose Uptake And The Expression Of Glucose Transporters In PC12 Cells" by Dwyer, D



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff   X   Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-1878					DRE 802 - Hearsay	00/00/2002 "Quetiapine-Associated Hyperglycemia and Hypertiglyceridemia" by Domon, S
P-1879					DRE 802 - Hearsay	00/00/2003 "A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States" by Buse, J (1-9)
P-1880					DRE 802 - Hearsay	00/00/1996 "ICI 204, 636, an Atypical Antipsychotic: Efficacy and Safety in a Multicenter, Placebo-Controlled Trial in Patients With Schizophrenia" by Borison, R
P-1881					DRE 802 - Hearsay	00/00/2003 Alnduction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake" by Dwyer, D
P-1882					DRE 802 - Hearsay	00/00/2005 "Antipsychotic drug-induced weight gain: development of an animal model" by Cope, M
P-1883					DRE 802 - Hearsay	00/00/2003 "Olanzapine Induces Insulin Resistance: Results From a Prospective Study" by Ebenbichler, C
P-1884					DRE 802 - Hearsay	00/00/1999 "Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis" by Allison, D
P-1885					DRE 802 - Hearsay	00/00/2007 "Efficacy and Comparative Effectiveness of OIF-Label Use of Atypical Antipsychotics" by Agency for Healthcare Research and Quality
P-1886					DRE 802 - Hearsay	00/00/2005 "Metabolic Dysregulation With Atypical Antipsychotics Occurs in the Absence of Underlying Disease" by Ader, M
P-1887					DRE 802 - Hearsay	00/00/2004 "Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes" by American Diabetes Association
P-1888					DRE 802 - Hearsay	00/00/2003 "Risks of Antipsychotics Detailed" by The Wall Street Journal
P-1889					DRE 802 - Hearsay	00/00/2006 "Atypical Antipsychotic Drugs Directly Impair Insulin Action in Adipocytes: Effects on Glucose Transport, Lipogenesis, and Antilipolysis" by Vestri, H
P-1890					DRE 802 - Hearsay	00/00/2008 "Major Changes in Glucose Metabolism, Including New-Onset Diabetes, Within 3 Months After Initiation of or Switch to Atypical Antipsychotic" by van Winkel, Ruud



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-1891					DRE 802 - Hearsay	00/00/2006 "The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England" by Twaites, B
P-1892					DRE 802 - Hearsay	00/00/2006 "Practical Treatment Information for Schizophrenia" by AM, J Psychiatry
P-1893					DRE 802 - Hearsay	00/00/2005 "Rapid Onset of Quetiapine-Induced Diabetic Ketoacidosis in an Elderly Patient" by Takahashi, M
P-1894					DRE 802 - Hearsay	00/00/2007 "Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATTIE Study" by Stroup, T (J-21)
P-1895					DRE 802 - Hearsay	00/00/2006 "Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation" by Stroup, T (J-20)
P-1896					DRE 802 - Hearsay	00/00/2003 "Evaluation of Insulin Sensitivity in Healthy Volunteers Treated with Olanzapine, Risperidone, or Placebo: A Prospective, Randomized Study Using the Two-Step" by Sowell, M
P-1897					DRE 802 - Hearsay	00/00/2002 "Hyperglycemic Clamp Assessment of Insulin Secretory Responses in Normal Subjects Treated with Olanzapine, Risperidone, or Placebo" by Sowell, M
P-1898					DRE 802 - Hearsay	00/00/1999 "New-Onset Diabetes Mellitus Associated With the Initiation of Quetiapine Treatment" by Sobel, M
P-1899					DRE 802 - Hearsay	00/00/2007 "Sidelining Safety-The FDA's Inadequate Response to the IOM" by Smith, S
P-1900					DRE 802 - Hearsay	00/00/2005 "Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients" by Smith, R
P-1901					DRE 802 - Hearsay	00/00/2008 "First- V. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis" by Smith, M
P-1902					DRE 802 - Hearsay	00/00/2004 "Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients" by Simpson, G



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff  Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-1903					DRE 802 - Hearsay	00/00/2005 "Undiagnosed Hypertglycemia in Patients Treated With Atypical Antipsychotics" by Sernyak, M (4-19)
P-1904					DRE 802 - Hearsay	00/00/2002 "Association of Diabetes Mellitus With Use of Atypical Neuroleptics in Treatment of Schizophrenia" by Sernyak, M
P-1905					DRE 802 - Hearsay	00/00/2008 "Differential Effects of Various Typical and Atypical Antipsychotics on Plasma Glucose and Insulin Levels in the Mouse" by Savoy, Y
P-1906					DRE 802 - Hearsay	00/00/2006 "Cost-Effectiveness of Second-generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia" by Rosenheck, R
P-1907					DRE 802 - Hearsay	00/00/2006 "Outcomes, Costs, and Policy Caution A Commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)" by Rosenheck, R
P-1908					DRE 802 - Hearsay	00/00/2005 "Preclinical Pharmacology of FMPD [6-Floro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzol[1azulene]" by Rasmussen, K
P-1909					DRE 802 - Hearsay	00/00/2006 "Do Certain Atypical Antipsychotics Increase the Risk of Diabetes? A Critical Review of 17 Pharmacoeconomic Studies" by Ramaswamy, K
P-1910					DRE 802 - Hearsay	00/00/2008 "FDA Guidance on Off-Label Promotion and the State of the Literature From Sponsors" by Psaty, B
P-1911					DRE 802 - Hearsay	00/00/2005 "Case Studies of Postmortem Quetiapine: Therapeutic or Toxic Concentrations?" by Parker, D
P-1912					DRE 802 - Hearsay	00/00/1969 "Drug Treatment of Psychosis" by Alexander, C
P-1913					DRE 802 - Hearsay	00/00/1980 "Drugs and The Treatment of Psychiatric Disorders" by Baldessarini, R
P-1914					DRE 802 - Hearsay	00/00/2005 "Second-Generation Antipsychotics and Metabolic Effects 12.3.2 Controlled Clinical Trials" by Newcomer, J
P-1915					DRE 802 - Hearsay	00/00/2005 "Second-Generation Antipsychotics and Metabolic Effects 7.3.3 Controlled Clinical Trials" by Newcomer, J
P-1916					DRE 802 - Hearsay	00/00/2005 "Second-Generation Antipsychotics and Metabolic Effects 6.2.4 Retrospective Database Analyses" by Newcomer, J



**JOINT TRIAL EXHIBIT LIST**

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-1917					DRE: 802 - Hearsay	00/00/2005 "Second-Generation (Atypical) Antipsychotics and Metabolic Effects A Comprehensive Literature Review" by Newcomer, J
P-1918					DRE: 802 - Hearsay	00/00/2006 "Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia" by Mel'vov, J (J-17)
P-1919	Nasrallah 6				DRE: 802 - Hearsay	00/00/2004 "Rate of New-Onset Diabetes Among Patients Treated With Atypical or Conventional Antipsychotic Medications for Schizophrenia" by Ollendorf, D
P-1920	Nasrallah 6				DRE: 802 - Hearsay	00/00/2007 "The Roles of Efficacy, Safety, and Tolerability in Antipsychotic Effectiveness: Practical Implications of the CATIE Schizophrenia Trial" by Nasrallah, H
P-1921					DRE: 802 - Hearsay	00/00/2007 "The Roles of Efficacy, Safety, and Tolerability in Antipsychotic Effectiveness: Practical Implications of the CATIE Schizophrenia Trial" by Nasrallah, H
P-1922					DRE: 802 - Hearsay	00/00/2006 "Randomized Controlled Trial of the Effect on Quality of Life of Second-vs First-Generation Antipsychotic Drugs in Schizophrenia" by Jones, P
P-1923					DRE: 802 - Hearsay	00/00/2006 "A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic" by Klein, D
P-1924					DRE: 802 - Hearsay	00/00/2006 "Mood Stabilizers and Atypical Antipsychotics: Bimodal Treatments for Bipolar Disorder" Ketter, T
P-1925					DRE: 802 - Hearsay	00/00/2007 "Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Acute Schizophrenia" by Kahn, R
P-1926					DRE: 802 - Hearsay	00/00/2004 "Quetiapine First report of pancreatitis: 3 case reports" by Gropper, J
P-1927					DRE: 802 - Hearsay	00/00/1997 "Superior effects of high dosing vs low dosing" by Small, J
P-1928					DRE: 802 - Hearsay	00/00/2007 "Metabolic Syndrome and Mental Illness" by Newcomer, J



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff  Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-1929					DRE 802 - Hearsay	00/00/0000 "Psychotic disorders and antipsychotics (Olanzapine combined with mood stabilizers in prevention of recurrence in bipolar disorder" by Tohen, M
P-1930					DRE 802 - Hearsay	00/00/2005 "Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid" by Lambert, B (1-15)
P-1931					DRE 802 - Hearsay	00/00/2006 "Antipsychotic drugs and diabetes B an application of the Austin Bradford Hill criteria" by Holt, R
P-1932	Nasrallah 12				DRE 802 - Hearsay	00/00/2006 "Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population" by Gianfrancesco, F
P-1933					DRE 802 - Hearsay	00/00/2006 "The Influence of Study Design on the Results of Pharmacoepidemiologic Studies of Diabetes" by Gianfrancesco, F
P-1934	Annct 31, Nasrallah 14				DRE 802 - Hearsay	00/00/2005 "Incidence of New-Onset Diabetes Mellitus Among Patients Receiving Atypical Neuroleptics in the Treatment of Mental Illness= by Miller, E
P-1935					DRE 802 - Hearsay	00/00/2003 "Antipsychotic-Induced Type 2 Diabetes: Evidence from a Large Health Plan Database" by Gianfrancesco, F (1-13)
P-1936					DRE 802 - Hearsay	00/00/2004 "Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population" by Ostbye, T
P-1937					DRE 802 - Hearsay	00/00/2004 "Frequency of New-Onset Diabetes Mellitus and Use of Antipsychotic Drugs Among Central Texas Veterans" by Barner, J (1-7)
P-1938					DRE 802 - Hearsay	00/00/2007 "Glucose Metabolism and Insulin Sensitivity" by Ratner, R
P-1939					DRE 802 - Hearsay	00/00/2004 "Prevalence of Diabetes Mellitus Among Outpatients With Severe Mental Disorders Receiving Atypical Antipsychotic Drugs" by Lambert, J
P-1940					DRE 802 - Hearsay	0/0/2008 "New-Onset type-2 diabetes associated with atypical antipsychotic medications" by Lambert
P-1941					DRE 802 - Hearsay	0/0/2008 "Economic Costs of Diabetes in the U.S. in 2007" by American Diabetes Association



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff   X   Defendant   X   Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-1942					DRE 802 - Hearsay	0/0/2008 "Extrapyrarnidal side-effects of antipsychotics in a randomized trial" by Miller
P-1943					DRE 802 - Hearsay	0/0/1997 "Quetiapine in patients with schizophrenia. A high and low-dose double-blind comparison with placebo. Serquel Study Group" by Small
P-1944					DRE 802 - Hearsay	0/0/2006 "Total and Component Health Care Costs in a Non-Medicare HMO Population of Patients With and Without Type 2 Diabetes and With and Without Macrovascular Disease" by Gandra
P-1945					DRE 802 - Hearsay	0/0/2007 "Third-Party Reimbursement for Diabetes Care, Self-Management Education, and Supplies" by American Diabetes Association
P-1946					DRE 802 - Hearsay	0/0/2007 "Canadian Adverse Reaction Newsletter-Quetiapine: pancreatitis and thrombocytopenia" by Canadian Adverse News Letter
P-1947					DRE 802 - Hearsay	0/0/2008 "Executive Summary: Standards of Medical Care in DiabetesC2008" by American Diabetes Association
P-1948					DRE 802 - Hearsay	0/0/2008 "Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: A flexible-dose, open-label pilot trial" by Katzman
P-1949					DRE 802 - Hearsay	0/0/2003 "Abstracts of the 1st International Conference on T" by Pharmacopsidemiology and drug safety
P-1950					DRE 802 - Hearsay	0/0/2008 "What Catic Found: Results From the Schizophrenia Trial" by Swartz
P-1951					DRE 802 - Hearsay	0/0/2003 "Patients on Atypical Antipsychotic Drugs: Another high-risk group for type 2 diabetes" by Lean
P-1952					DRE 802 - Hearsay	00/00/2005 "National Diabetes Fact Sheet" by Center for Disease Control
P-1953					DRE 802 - Hearsay	00/00/2007 "Depression in Schizophrenia" by Mauri, M
P-1954					DRE 802 - Hearsay	00/00/2005 "Antipsychotic drugs and diabetes" by Holl, R
P-1955					DRE 802 - Hearsay	00/00/2003 "A Social Science Perspective on Gifts to Physicians From Industry" by Dana, J



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-1956					DRE 802 - Hearsay	00/00/2007 "Drug Companies Improperly Influence Continuing Medical Education" by Coverage Access
P-1957					DRE 802 - Hearsay	00/00/2000 "The Importance of Doctors= and Patients= Preferences in Prescription" by Coscelli, A
P-1958					DRE 802 - Hearsay	00/00/2003 "The Uncertain Future of Continuing Medical Education" by Van Harrison, R
P-1959					DRE 802 - Hearsay	00/00/1982 "Scientific versus Commercial Sources of Influence on the Prescribing Behavior" by Avorn, J
P-1960					DRE 802 - Hearsay	00/00/2007 "A National Survey of Physician" by Campbell, E
P-1961					DRE 802 - Hearsay	00/00/2002 "Demand Effects of Recent Changes in Prescription Drug Promotion" by Rosenthal, M
P-1962					DRE 802 - Hearsay	00/00/2003 "Direct-to-Consumer Advertising and Shared Liability for Pharmaceutical Manufacturers" by Mello, M
P-1963					DRE 802 - Hearsay	00/00/2004 "Financial Conflicts of Interest in Physicians= Relationships with the Pharmaceutical" by Studdert, JD
P-1964					DRE 802 - Hearsay	00/00/2007 "Following the Script: How Drug Reps Make Friends and Influence Doctors" by Fugh-Berman, A
P-1965					DRE 802 - Hearsay	00/00/1954 "Optimal Advertising and Optimal Quality" by Dorfman, R
P-1966					DRE 802 - Hearsay	00/00/2000 "Physicians and the Pharmaceutical Industry" by Wazana, A
P-1967					DRE 802 - Hearsay	00/00/1988 "Physician knowledge, attitudes, and behavior related to reporting adverse drug events" by Rogers, A
P-1968					DRE 802 - Hearsay	00/00/1994 "Physicians= behavior and their interactions with drug companies" by Chen, M
P-1969					DRE 802 - Hearsay	00/00/2001 "Promotion of Prescription Drugs and Its Impact on Physicians= Choice Behavior" by Gonul, F
P-1970					DRE 802 - Hearsay	00/00/2002 "Promotion of Prescription Drugs to Consumers" by Rosenthal, M
P-1971					DRE 802 - Hearsay	00/00/2005 "Glycemic Control and Cardiovascular DiseaseC Should We Reassess Clinical Goals" by Celalu



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant \_\_\_\_\_ Joint \_\_\_\_\_ Court \_\_\_\_\_  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-1972					DRE 802 - Hearsay	00/00/2007 "Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics" by Agency for Healthcare Research and Quality
P-1973					DRE 802 - Hearsay	00/00/2007 "Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics-Executive Summary" Agency for Healthcare Research and Quality
P-1974					DRE 802 - Hearsay	A efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLIDER II study)" by Thase, ME
P-1975					DRE 802 - Hearsay	09/00/2000 New-Onset Diabetes Mellitus Associated with Quetiapine by Procyshyn, R.
P-1976					DRE 802 - Hearsay	00/00/2002 New-Onset Diabetes and Ketoacidosis with Atypical Antipsychotics by Wilson, D.
P-1977					DRE 802 - Hearsay	05/00/2003 Type 2 Diabetes Mellitus Induced by an Atypical Antipsychotic Medication by Sneed, K
P-1978					DRE 802 - Hearsay	08/00/2003 Antipsychotic-Induced Type 2 Diabetes: Evidence from a Large Health Plan Database by Gianfrancesco, F.
P-1979					DRE 802 - Hearsay	00/00/2005 Incidence of Diabetes in a General Practice Population: A Database Cohort Study on the Relationship with Haloperidol, Olanzapine, Risperidone or Quetiapine Exposure by Sacchetti, E.
P-1980					DRE 802 - Hearsay	02/01/2008 Antipsychotics, Glycemic Disorders, and Life-Threatening Diabetic Events: A Bayesian Data-Mining Analysis of the FDA Adverse Event Reporting System (1968-2004) by DuMouchel, W.
P-1981					DRE 802 - Hearsay	03/00/2008 Major Changes in Glucose Metabolism, Including New-Onset Diabetes, Within 3 Months After Initiation of or Switch to Atypical Antipsychotic Medication in Patients with Schizophrenia and Schizoaffective Disorder by van Winkel, R.
P-1982					DRE 802 - Hearsay	00/00/2003 Diabetes Mellitus Associated with Atypical Anti-Psychotic Medications by Clark, C.



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff  Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-1983					DRE 802 - Hearsay	00/00/2008 Impact of Antipsychotic Treatment on Nonfasting Triglycerides in the CATIE Schizophrenia Trial Phase I by Meyer, J.
P-1984					DRE 802 - Hearsay	00/00/2007 Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week Comparison by Mefkoy, J. (J-18)
P-1985						Intentionally Blank
P-1986	Nasrallah 11				DRE 802 - Hearsay	00/00/2006 Metabolic Findings From the CATIE Trial and Their Relation to Tolerability by Nasrallah, H.
P-1987					DRE 802 - Hearsay	00/00/2001 Diabetes Mellitus Associated with Atypical Antipsychotic Medications: New Case Report and Review of the Literature by Muench, J.
P-1988					DRE 802 - Hearsay	00/00/2002 Assessment of Independent Effect of Olanzapine and Risperidone on Risk of Diabetes among Patients with Schizophrenia: Population Based Nested Case-Control Study by Koro, C.
P-1989					DRE 802 - Hearsay	00/00/2002 Incident Diabetes Associated with Antipsychotic Use in the United Kingdom General Practice Research Database by Komegay, C.
P-1990					DRE 802 - Hearsay	00/00/2003 Hyperglycemia and Hypertriglyceridemia in Real World Patients on Antipsychotic Therapy by Gupta, S. (J-14)
P-1991					DRE 802 - Hearsay	00/00/2007 Abnormal Glucose Metabolism in Patients Treated with Antipsychotics by Scheen, AJ
P-1992					DRE 802 - Hearsay	00/00/2007 Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers by Saehar, J.
P-1993					DRE 802 - Hearsay	00/00/2008 Atypical Antipsychotic Drugs Induce Derangements in Glucose Homeostasis by Acutely Increasing Glucagon Secretion and Hepatic Glucose Output in the Rat by Smith GC
P-1994					DRE 802 - Hearsay	00/00/2005 Glucose Metabolism in Patients with Schizophrenia Treated with Atypical Antipsychotic Agents: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis by Henderson, D.



## JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant  Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-1995						00/00/2006 Chronic Administration of Olanzapine Induces Metabolic and Food Intake Alterations: a Mouse Model of the Atypical Antipsychotic-Associated Adverse Effects by Cocurello, R.
P-1996					DRE 802 - Hearsay	00/00/2002 Glucose Intolerance with Atypical Antipsychotics by Hedemalm, K.
P-1997					DRE 802 - Hearsay	00/00/2006 Acute Effects of Atypical Antipsychotics on Whole-Body Insulin Resistance in Rats: Implications for Adverse Metabolic Effects by Houseknecht, K.
P-1998					DRE 802 - Hearsay	00/00/2003 H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs by Kroeze, WK
P-1999					DRE 802 - Hearsay	00/00/2006 The Early Effect of Olanzapine and Risperidone on Insulin Secretion in Atypical-Naive Schizophrenic Patients by Chiu, CC
P-2000					DRE 802 - Hearsay	00/00/1997 A Comparison of Quetiapine and Chlorpromazine in the Treatment of Schizophrenia by Link
P-2001					DRE 802 - Hearsay	00/00/2009 Second-Generation Versus First-Generation Antipsychotic Drugs for Schizophrenia: A Meta-Analysis by Leucht, S.
P-2002					DRE 802 - Hearsay	00/00/2005 Atypical Antipsychotics and Glucose Homeostasis by Bergman, R.
P-2003					DRE 802 - Hearsay	00/00/2006 Differential Metabolic Effects of Antipsychotic Treatments by Haupt, D.
P-2004					DRE 802 - Hearsay	00/00/2001 Hyperglycemia and Antipsychotic Medications by Haupt, D.
P-2005					DRE 802 - Hearsay	00/00/2005 Undiagnosed Hyperglycemia in Patients Treated with Atypical Antipsychotics by Semyak, M. (J-19)
P-2006					DRE 802 - Hearsay	00/00/2002 Decrease of Energy Expenditure Causes Weight Increase in Olanzapine Treatment - A Case Study by Virkkunen, M.
P-2007					DRE 802 - Hearsay	00/00/2001 Bodyweight Gain with Atypical Antipsychotics: A Comparative Review by Wetterling, T.



## JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff X Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-2008					DRE: 802 - Hearsay	00/00/2002 The Effects of Novel Antipsychotics on Glucose and Lipid Levels by Wishing, D.
P-2009					DRE: 802 - Hearsay	04/00/2007 Quetiapine and Long-Term Weight Change: A Comprehensive Data Review of Patients with Schizophrenia by Brecher, M.
P-2010					DRE 402 - Relevance	AZ Employees
P-2011					No Objection	Expert Report of M. James Lenhard
P-2012					DRE 802 - Hearsay	03/29/2008 Effectiveness of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: An Open Randomised Clinical Trial
P-2013					DRE 802 - Hearsay	APA Poster Presentations, Washington, DC, USA (Lenhard 0888 - Lenhard 0891)
P-2014					AstraZeneca objects to this exhibit on the grounds that Plaintiff's description does not permit AstraZeneca to identify a particular exhibit. AstraZeneca objects to the image provide by plaintiff under DRE: 802 - Hearsay, and the document as described under DRE 402 - Relevance DRE 403 - Prejudicial (MIL. re: Irrelevant Marketing)	05/00/2008 Seroquel Marketing Documents
P-2015					DRE: 802 - Hearsay	05/00/2006 Glucose Metabolism in Patients with Schizophrenia Treated with Olanzapine or Quetiapine: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis
P-2016					No Objection	04/01/2000 Code of Federal Regulations - Title 21, volume 4, Parts 200 to 299
P-2017					No Objection	10/02/2008 Expert Report of Marianne Mann, M.D.
P-2018					DRE: 402 - Relevance	Exhibit C to Expert Report



**JOINT TRIAL EXHIBIT LIST**

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-2019					DRE 402 - Relevance DRE 403 - Prejudicial	Invoices for Mann Services
P-2020					No Objection	Curriculum Vitae of Marianne Mann
P-2021					No objection	Exhibit B: Testimony in Past 4 Years
P-2022					No Objection	01/01/2008 Serquel Tablets: Highlights of Prescribing Information
P-2023					DRE 402 - Relevance DRE 403 - Prejudicial DRE 407 - Subsequent remedial measures	12/18/2008 FDA Letter to AZ re Reformulating Supplemental Drug Application (D339-L01168670-0001)
P-2024					DRE 402 - Relevance DRE 403 - Prejudicial	08/14/2008 Olanzapine info for Tablets, Orally Disintegrating Tablets, and Injection
P-2025	Arnold 15				Relevance, Prejudicial, Confusion, FRE 401 and 403	12/14/2004. Safety Query Response - Review of All Pediatric Reports for Serquel
P-2026	Beamish 27				Relevance, Prejudicial (MIL. re irrelevant Marketing)	09/10/2002. Email string - Trial 41 dissemination. (AZ/SER3777919 - AZ/SER3777920)
P-2027	Brecher 5				Relevance, Prejudicial, Confusion, FRE 401 and 403	7/19/2001 Email chain involving Wayne Gelle, Barry Arnold and Martin Brecher re: Stefan Carlsson's suggestion following SERM re: removal of "limited" from weight gain. (SQJL:002594936)
P-2028	Brecher 12				Relevance, Prejudicial (MIL. re irrelevant Marketing)	3/19/01 Email String from Brecher to Travers regarding Serquel Weight Neutral Claim
P-2029	Mckenna 22				No objection	Printout of www.astrazenecatrials.com website trial summaries. Serquel package insert.
P-2030	Mckenna 25				No objection	Henry Hasrallah, M.D., 1099's from AstraZeneca for years 1999 to 2007.
P-2031	Nasrallah 4				Privacy, Relevance, FRE 401 and 403	00/00/2005. Schizophrenia Research editorial entitled, "The CATIE schizophrenia effectiveness trial" by Nasrallah, H.
P-2032	Nasrallah 7				Hearsay	6/13/1997. Review and Evaluation of Clinical Data. Quetiapine Clinical Review by Andrew Mosholder, M.D.
P-2033	Nasrallah 17				No objection	Nasrallah, H. A Review of the Effect of Atypical Antipsychotics on Weight. <i>Psychoneuroendocrinology</i> . 2003; 28: 83-96.
P-2034	Nasrallah 18				No objection	



## JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-2035	Nasrallah 19				No objection	Nasrallah, H. Efficacy, Safety, and Tolerability of Quetiapine in Patients with Schizophrenia. <i>Journal of Clinical Psychiatry</i> . 2002; 63(suppl.13): 12-20.
P-2036	Nasrallah 21				No objection	00/00/2000. Clinical Study, "The Weight Profile of Serquel Over the Long Term". (AZSER 10427821 - AZSER10427823)
P-2037	Nasrallah 33				Relevance, FRI: 401 and 403	6/11/2007. E-mail from Henry Nasrallah to Jonathan Fox regarding standard honorarium per day and how payment is to be made. (NAS003759-NAS003760)
P-2038	Nasrallah PX 36				Relevance, FRI: 401 and 403	6/6/2007. E-mail from Henry Nasrallah to Cheng Hui Kang regarding lecture schedule and standard honorarium per day. (NAS004995-NAS005010)
P-2039	Nasrallah PX 38				Relevance, FRI: 401 and 403	8/27/2007. E-mail from Henry Nasrallah to Angelika Stafflage. (NAS003993-NAS003995)
P-2040	Schwartz 7				Relevance, Prejudicial (MIL. re irrelevant Marketing)	12/18/2000. Serquel Strategy Summary. (AZSER 10769859 - AZSER 10769861)
P-2041	Schwartz 42				Relevance, Prejudicial (MIL. re irrelevant Marketing)	09/09/2002. Email from Simon Hagger, Serquel Global Brand Manager, describing the SR Communications Team's meeting regarding the dissemination of Trial 41 data to external partners. (AZSER377913)
P-2042	Zook 9				No objection	08/18/2000. Email string regarding SERM Minutes with Justification Document and Safety Position Paper. (AZSER6971505 - AZSER6971528)
P-2043					Not timely disclosed; further objection reserved	Clinical Study Report Errata List D1448C00001 (MOONSTONE Study) (D339-1.01103312)
P-2044					Not timely disclosed; further objection reserved	Clinical Study Report Errata List D1448C00002 (DIAMOND Study) D339-1.01122418
P-2045					Not timely disclosed; further objection reserved	Clinical Study Report D1448C00003 (OPAL Study) D339-1.00713856
P-2046					Not timely disclosed; further objection reserved	Clinical Study Report Errata List D1448C00004 (AMBER Study) D339-1.01122420
P-2047					Not timely disclosed; further objection reserved	Clinical Study Report D1448C00005 (AMETHYST Study) AZSER24966991 - AZSER24967272



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff  Defendant  Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-2048					Not timely disclosed; further objection reserved	Clinical Study Report Errata List D1448C00006 (PEARL Study) D339-L01103234
P-2049					Not timely disclosed; further objection reserved	Clinical Study Report D1448C00007 (ONYX Study) D339-L00702569
P-2050					Not timely disclosed; further objection reserved	Clinical Study Report D1448C00009 (TITANIUM Study) D339-L01116198
P-2051					Not timely disclosed; further objection reserved	Clinical Study Report D1448C00011 (SILVER Study) D339-L01104105
P-2052					Not timely disclosed; further objection reserved	Clinical Study Report 50771L/0041 (Trial 41) D339-L00795402
P-2053					Not timely disclosed; further objection reserved	Clinical Study Report D1444C00132 (D339-L00701472)
P-2054					Not timely disclosed; further objection reserved	Clinical Study Report D1444C00133 (D339-L00718537)
P-2055					Not timely disclosed; further objection reserved	Clinical Study Protocol D1447C00144 (D339-L00773834)
P-2056					Relevance More prejudicial than probative; waste of time; jury confusion. Not timely disclosed; further objection reserved	Discussion Document - Extrapyramidal Symptoms in General Anxiety Disorder D339-L01100548
P-2057					Relevance More prejudicial than probative; waste of time; jury confusion. Not timely disclosed; further objection reserved	Discussion Document - Seroquel and Seroquel XR and Discontinuation Symptoms D339-L01100687



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-2058					Relevance More prejudicial than probative; waste of time; jury confusion. Not timely disclosed; further objection reserved	Addendum to: Discussion Document - Serquel and Serquel XR and Discontinuation Symptoms D339-L01104418
P-2059					Not timely disclosed; further objection reserved	Quetiapine Fumarate Extended Release US MDD Table - MADRS response at Week 6 (Studies 1 and 2) D339-L01110479
P-2060					Relevance More prejudicial than probative; waste of time; jury confusion. Not timely disclosed; further objection reserved	Discussion Document - Serquel XR and Extrapyramidal symptoms in Elderly patients with Major Depressive Disorder D339-L01112845
P-2061					Not timely disclosed; further objection reserved	2.7.3.6 Appendix to 2.7.3 - Pooled Efficacy Data: Quetiapine Fumarate Extended Release US MDD D339-L01118788
P-2062					Not timely disclosed; further objection reserved	2.7.4.7 Appendix to 2.7.4 - Pooled Safety Data Tables: Quetiapine Fumarate Extended Release US MDD D339-L01150746
P-2063					Not timely disclosed; further objection reserved	2.7.4 Summary of Clinical Safety - Quetiapine XR in the Treatment of Generalized Anxiety Disorder D339-L01153845
P-2064					Relevance More prejudicial than probative; waste of time; jury confusion. Not timely disclosed; further objection reserved	Ematis Re: MDD Sem topics F339-E12110515
P-2065					Not timely disclosed; further objection reserved	Ematis Re: diabetes in 126/127 F339-E15811265
P-2066					Not timely disclosed; further objection reserved	Ematis Re: Lab tables in the individual CSRs for MDD/GAD1 F339-E15848960
P-2067					Not timely disclosed; further objection reserved	Quetiapine Fumarate Extended Release US MDD Table EA001a - Efficacy Results at Week 6 F339-E17570378



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Supplated Admissions	Description of Exhibit
P-2068					Not timely disclosed; further objection reserved	Quetiapine Fumarate Extended Release US MDD Table SA006a - Exposure to Study Medication Acute Monotherapy Pool Safety Population F339-E17570380
P-2069					Hearsay Not timely disclosed; further objection reserved	Emails Re: ADAA poster: GAD Study 11 (Silver) with poster F339-E17808034; F339-E17808035
P-2070					Not timely disclosed; further objection reserved	Emails Re: PRB Slides - Draft 2 F339-E18024279
P-2071					Not timely disclosed; further objection reserved	Seroquel Commercial Support Team - Technical Document (TD434) - Effects on MADRS Total scores in MDD patients with agitation in study 1, 2, 3, 4, 6 and 7 (S339-E02150435)
P-2072					Not timely disclosed; further objection reserved	Seroquel Commercial Support Team - Technical Document (TD438) - Analysis of outcome variables for patient with MDD S339-E02150460
P-2073					Relevance More prejudicial than probative; waste of time; jury confusion. Not timely disclosed; further objection reserved	Discussion Document - Seroquel XR and Extrapyramidal symptoms in Elderly patients with Generalized Anxiety Disorder S339-L02419420-E003
P-2074					Not timely disclosed; further objection reserved	Slides - "MDD Efficacy and Tolerability - Where can Seroquel Win?" SQ1E1D00154058
P-2075					Not timely disclosed; further objection reserved	Rationale for the Major Depressive Disorder and Generalized Anxiety Disorder Programs SQ1E1D00681374
P-2076					Not timely disclosed; further objection reserved	Emails Re: DRAFT summary of ACTION items from 4/13 discussion of diabetes, MDD/GAD SQ1E1D01015934
P-2077					Lack of Authentication Not timely disclosed; further objection reserved	Slides - "Post-hoc evaluation of 126 and 127 data" SQ1P04561482
P-2078					Not timely disclosed; further objection reserved	Summary of additional safety questions in studies 126 & 127, including an analysis plan, final analyses and brief conclusions AZSER23353147 - AZSER23353223



**JOINT TRIAL EXHIBIT LIST**

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
**Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION**

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-2079					Relevance More prejudicial than probative; waste of time; jury confusion. Hearsay Not timely disclosed; further objection reserved	CRS Report for Congress - The Food and Drug Administration: Budget and Statutory History, FY 1980-FY2007
P-2080					Hearsay Personal Knowledge (lack of foundation) Requirement of Authentication (lack of foundation) More prejudicial than probative; waste of time; jury confusion. Object to the unidentified handwriting Not timely disclosed; further objection reserved	"Comparative Effectiveness of Antipsychotic Drugs," Lieberman
P-2081					Relevance More prejudicial than probative; waste of time; jury confusion. Not timely disclosed; further objection reserved	Demonstrative - United States Supreme Court, Wyeth v. Levine, 2009
P-2082					No Objection	Brian Tulloch, M.D., CV



**JOINT TRIAL EXHIBIT LIST**

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-2083					More prejudicial than probative; waste of time; jury confusion. Hearsay Lack of Personal Knowledge (lack of foundation) Requirement of Authentication (lack of foundation)	DM Inducing Effects of Seroquel/Quetiapine
P-2084					Hearsay Lack of Personal Knowledge (lack of foundation) Requirement of Authentication (lack of foundation)	Antipsychotics' Link to Weight Gain Found AMA March 27 2007
P-2085					Hearsay Lack of Personal Knowledge (lack of foundation) Requirement of Authentication (lack of foundation)	Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase
P-2086					Hearsay Lack of Personal Knowledge (lack of foundation) Requirement of Authentication (lack of foundation)	Clinical Risk Factors, DNA Variants and the Development of Type 2 Diabetes
P-2087					Hearsay Lack of Personal Knowledge (lack of foundation) Requirement of Authentication (lack of foundation)	JAMA The Continuing Epidemic of Obesity and Diabetes in the United States



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff   X   Defendant   X   Joint \_\_\_\_\_ Court  
 Case No. 6:06-ev-1769-ACC-DAB  
**Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION**

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-2088					Hearsay Lack of Personal Knowledge (lack of foundation) Requirement of Authentication (lack of foundation)	The spurious advance of antipsychotic drug therapy
P-2089					Hearsay More prejudicial than probative; waste of time; jury confusion. Lack of Personal Knowledge (lack of foundation) Requirement of Authentication (lack of foundation) Object to the unidentified handwriting	Type 2 Diabetes is NOT a Mild Disease
P-D0001					Foundation Unduly prejudicial: Inaccurate/misleading	Plaintiff's Demonstrative Exhibit of Terms.
P-D0002					Foundation Source document not identified Relevance Rule 702 and Rule 703 objection; incomplete and unreliable summary of the applicable science.	Plaintiff's Demonstrative Exhibit of Vital Signs and Weight Assessment by Trial.



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff  Defendant  Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-ID00003					Unduly prejudicial; Inaccurate/ misleading Foundation Rule 403 Rule 803 Rule 702 and Rule 703 objection; incomplete and unreliable summary of the applicable science.	Plaintiff's Demonstrative Exhibit of Observational Studies.
P-ID00004					Foundation Rule 403 Incomplete summary Rule 803 Hearsay Rule 702 and Rule 703 objection; incomplete and unreliable summary of the applicable science. Unduly prejudicial; Inaccurate/ misleading	Plaintiff's Demonstrative Exhibit of Weight Changes in AZ Studies.
P-ID00005					No Objection	Plaintiff's Demonstrative Exhibit of Atypical Antipsychotics.
P-ID00006					Unduly prejudicial; Inaccurate/ misleading; commentary about evidence Rule 403 Foundation Rule 702 and Rule 703 objection; incomplete and unreliable summary of the applicable science.	Plaintiff's Demonstrative Exhibit of Studies Summary Chart.
P-ID00007					Hearsay Foundation Assumes facts not in evidence Unduly prejudicial; Inaccurate/ misleading Mischaracterizes evidence Metabolic Effects slides are also objectionable pursuant to Rules 702-03	Plaintiff's Demonstrative Exhibit of "Seroquel: An Overview of Pharmacology, Toxicology and Human Health Risks".



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-D00008					Hearsay Rule 402 Relevance Unduly prejudicial: Inaccurate/ misleading Rule 403 Foundation Rule 702 Rule 703	Plaintiff's Demonstrative Exhibit of "Current Criteria for Diagnosis of Diabetes".
P-L/T001						RESERVED
P-L/T002						RESERVED
P-L/T003						RESERVED
P-L/T004						RESERVED
P-L/T005						RESERVED
P-L/T006						RESERVED
P-L/T007						RESERVED
P-L/T008						RESERVED
P-L/T009						RESERVED
P-L/T010						RESERVED
P-L/T011						RESERVED
P-L/T012						RESERVED
P-L/T013						RESERVED
P-L/T014						RESERVED
P-L/T015						RESERVED
P-L/T016						RESERVED
P-L/T017						RESERVED
P-L/T018						RESERVED
P-L/T019						RESERVED
P-L/T020						RESERVED
P-L/T021						RESERVED
P-L/T022						RESERVED
P-L/T023						RESERVED
P-L/T024						RESERVED
P-L/T025						RESERVED
P-L/T026						RESERVED
P-L/T027						RESERVED



**JOINT TRIAL EXHIBIT LIST**

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-L.T028						RESERVED
P-L.T029						RESERVED
P-L.T030						RESERVED
P-L.T031						RESERVED
P-L.T032						RESERVED
P-L.T033						RESERVED
P-L.T034						RESERVED
P-L.T035						RESERVED
P-L.T036						RESERVED
P-L.T037						RESERVED
P-L.T038						RESERVED
P-L.T039						RESERVED
P-L.T040						RESERVED
P-L.T041						RESERVED
P-L.T042						RESERVED
P-L.T043						RESERVED
P-L.T044						RESERVED
P-L.T045						RESERVED
P-L.T046						RESERVED
P-L.T047						RESERVED
P-L.T048						RESERVED
P-L.T049						RESERVED
P-L.T050						RESERVED
P-L.T051						RESERVED
P-L.T052						RESERVED
P-L.T053						RESERVED
P-L.T054						RESERVED
P-L.T055						RESERVED
P-L.T056						RESERVED
P-L.T057						RESERVED
P-L.T058						RESERVED
P-L.T059						RESERVED



JOINT TRIAL EXHIBIT LIST

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-L.T060						RESERVED
P-L.T061						RESERVED
P-L.T062						RESERVED
P-L.T063						RESERVED
P-L.T064						RESERVED
P-L.T065						RESERVED
P-L.T066						RESERVED
P-L.T067						RESERVED
P-L.T068						RESERVED
P-L.T069						RESERVED
P-L.T070						RESERVED
P-L.T071						RESERVED
P-L.T072						RESERVED
P-L.T073						RESERVED
P-L.T074						RESERVED
P-L.T075						RESERVED
P-L.T076						RESERVED
P-L.T077						RESERVED
P-L.T078						RESERVED
P-L.T079						RESERVED
P-L.T080						RESERVED
P-L.T081						RESERVED
P-L.T082						RESERVED
P-L.T083						RESERVED
P-L.T084						RESERVED
P-L.T085						RESERVED
P-L.T086						RESERVED
P-L.T087						RESERVED
P-L.T088						RESERVED
P-L.T089						RESERVED
P-L.T090						RESERVED
P-L.T091						RESERVED



JOINT TRIAL EXHIBIT LIST

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-L/T092						RESERVED
P-L/T093						RESERVED
P-L/T094						RESERVED
P-L/T095						RESERVED
P-L/T096						RESERVED
P-L/T097						RESERVED
P-L/T098						RESERVED
P-L/T099						RESERVED
P-L/T0100						RESERVED
P-L/T0101						RESERVED
P-L/T0102						RESERVED
P-L/T0103						RESERVED
P-L/T0104						RESERVED
P-L/T0105						RESERVED
P-L/T0106						RESERVED
P-L/T0107						RESERVED
P-L/T0108						RESERVED
P-L/T0109						RESERVED
P-L/T0110						RESERVED
P-L/T0111						RESERVED
P-L/T0112						RESERVED
P-L/T0113						RESERVED
P-L/T0114						RESERVED
P-L/T0115						RESERVED
P-L/T0116						RESERVED
P-L/T0117						RESERVED
P-L/T0118						RESERVED
P-L/T0119						RESERVED
P-L/T0120						RESERVED
P-L/T0121						RESERVED
P-L/T0122						RESERVED
P-L/T0123						RESERVED



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant  Joint \_\_\_\_\_ Court \_\_\_\_\_  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-L.T0124						RESERVED
P-L.T0125						RESERVED
P-L.T0126						RESERVED
P-L.T0127						RESERVED
P-L.T0128						RESERVED
P-L.T0129						RESERVED
P-L.T0130						RESERVED
P-L.T0131						RESERVED
P-L.T0132						RESERVED
P-L.T0133						RESERVED
P-L.T0134						RESERVED
P-L.T0135						RESERVED
P-L.T0136						RESERVED
P-L.T0137						RESERVED
P-L.T0138						RESERVED
P-L.T0139						RESERVED
P-L.T0140						RESERVED
P-L.T0141						RESERVED
P-L.T0142						RESERVED
P-L.T0143						RESERVED
P-L.T0144						RESERVED
P-L.T0145						RESERVED
P-L.T0146						RESERVED
P-L.T0147						RESERVED
P-L.T0148						RESERVED
P-L.T0149						RESERVED
P-L.T0150						RESERVED
P-L.T0151						RESERVED
P-L.T0152						RESERVED
P-L.T0153						RESERVED
P-L.T0154						RESERVED
P-L.T0155						RESERVED



**JOINT TRIAL EXHIBIT LIST**

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-L.T0156						RESERVED
P-L.T0157						RESERVED
P-L.T0158						RESERVED
P-L.T0159						RESERVED
P-L.T0160						RESERVED
P-L.T0161						RESERVED
P-L.T0162						RESERVED
P-L.T0163						RESERVED
P-L.T0164						RESERVED
P-L.T0165						RESERVED
P-L.T0166						RESERVED
P-L.T0167						RESERVED
P-L.T0168						RESERVED
P-L.T0169						RESERVED
P-L.T0170						RESERVED
P-L.T0171						RESERVED
P-L.T0172						RESERVED
P-L.T0173						RESERVED
P-L.T0174						RESERVED
P-L.T1175						RESERVED
P-L.T1176						RESERVED
P-L.T1177						RESERVED
P-L.T1178						RESERVED
P-L.T1179						RESERVED
P-L.T1180						RESERVED
P-L.T1181						RESERVED
P-L.T1182						RESERVED
P-L.T1183						RESERVED
P-L.T1184						RESERVED
P-L.T1185						RESERVED
P-L.T1186						RESERVED
P-L.T1187						RESERVED



JOINT TRIAL EXHIBIT LIST

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-L/T188						RESERVED
P-L/T189						RESERVED
P-L/T190						RESERVED
P-L/T191						RESERVED
P-L/T192						RESERVED
P-L/T193						RESERVED
P-L/T194						RESERVED
P-L/T195						RESERVED
P-L/T196						RESERVED
P-L/T197						RESERVED
P-L/T198						RESERVED
P-L/T199						RESERVED
P-L/T200						RESERVED
P-L/T201						RESERVED
P-L/T202						RESERVED
P-L/T203						RESERVED
P-L/T204						RESERVED
P-L/T205						RESERVED
P-L/T206						RESERVED
P-L/T207						RESERVED
P-L/T208						RESERVED
P-L/T209						RESERVED
P-G 1						RESERVED
P-G 1 HB						RESERVED
P-G 2						RESERVED
P-G 2A						RESERVED
P-G 2B						RESERVED
P-G 2C						RESERVED
P-G 3						RESERVED
P-G 3A						RESERVED
P-G 3B						RESERVED
P-G 4						RESERVED



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff   X   Defendant \_\_\_\_\_ Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-G5						RESERVED
P-G5A						RESERVED
P-G5B						RESERVED
P-G5C						RESERVED
P-G5D						RESERVED
P-G5E						RESERVED
P-G5F						RESERVED
P-G6						RESERVED
P-G7						RESERVED
P-G8						RESERVED
P-G9						RESERVED
P-G10						RESERVED
P-G11						RESERVED
P-G11A						RESERVED
P-G11C						RESERVED
P-G12						RESERVED
P-G12A						RESERVED
P-G13						RESERVED
P-G14						RESERVED
P-G15						RESERVED
P-G16						RESERVED
P-G17						RESERVED
P-G18						RESERVED
P-G19						RESERVED
P-G20						RESERVED
P-G21						RESERVED
P-G22						RESERVED
P-G23						RESERVED
P-G23A						RESERVED
P-G24						RESERVED
P-G24A						RESERVED
P-G25						RESERVED



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff  Defendant  Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-G26						RESERVED
P-G27						RESERVED
P-G27A						RESERVED
P-G27B						RESERVED
P-G27C						RESERVED
P-G27D						RESERVED
P-G27E						RESERVED
P-G28						RESERVED
P-G 29B						RESERVED
P-G29						RESERVED
P-G29A						RESERVED
P-G29C						RESERVED
P-G29D						RESERVED
P-G29E						RESERVED
P-G30						RESERVED
P-G31						RESERVED
P-G32						RESERVED
P-G33						RESERVED
P-G33A						RESERVED
P-G33B						RESERVED
P-G33C						RESERVED
P-G33D						RESERVED
P-G33E						RESERVED
P-G33F						RESERVED
P-G34						RESERVED
P-G35						RESERVED
P-G36						RESERVED
P-G37						RESERVED
P-G37A						RESERVED
P-G37B						RESERVED
P-G37C						RESERVED
P-G37D						RESERVED



JOINT TRIAL EXHIBIT LIST

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-G37E						RESERVED
P-G37F						RESERVED
P-G37G						RESERVED
P-G38						RESERVED
P-G39						RESERVED
P-G40						RESERVED
P-G41						RESERVED
P-G42						RESERVED
P-G43						RESERVED
P-G43A						RESERVED
P-G43B						RESERVED
P-G43C						RESERVED
P-G43D						RESERVED
P-G43E						RESERVED
P-G43F						RESERVED
P-G43G						RESERVED
P-G43H						RESERVED
P-G43I						RESERVED
P-G43J						RESERVED
P-G43K						RESERVED
P-G43L						RESERVED
P-G43M						RESERVED
P-G43N						RESERVED
P-G43O						RESERVED
P-G44						RESERVED
P-G45						RESERVED
P-G45A						RESERVED
P-G46						RESERVED
P-G47						RESERVED
P-G48						RESERVED
P-G48A						RESERVED
P-G48B						RESERVED



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant  Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-G48C						RESERVED
P-G48D						RESERVED
P-G49						RESERVED
P-G50						RESERVED
P-G51						RESERVED
P-G52						RESERVED
P-G53						RESERVED
P-G53A						RESERVED
P-G53B						RESERVED
P-G53C						RESERVED
P-G53D						RESERVED
P-G53E						RESERVED
P-G53F						RESERVED
P-G53G						RESERVED
P-G53H						RESERVED
P-G53I						RESERVED
P-G53J						RESERVED
P-G53K						RESERVED
P-G54						RESERVED
P-G55						RESERVED
P-G56						RESERVED
P-G57						RESERVED
P-G58						RESERVED
P-G59						RESERVED
P-G59A						RESERVED
P-G59B						RESERVED
P-G59C						RESERVED
P-G59D						RESERVED
P-G60						RESERVED
P-G61						RESERVED
P-G62						RESERVED
P-G63						RESERVED



JOINT TRIAL EXHIBIT LIST

Government          Plaintiff          Defendant           Joint          Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
P-G64						RESERVED
P-G65						RESERVED
P-G66						RESERVED
P-G67						RESERVED
P-G68						RESERVED
P-G69						RESERVED
P-G70						RESERVED
P-G70A						RESERVED
P-G70B						RESERVED
P-G70C						RESERVED
P-G70D						RESERVED
P-G70E						RESERVED
P-G70F						RESERVED
P-G71						RESERVED
P-G72						RESERVED
P-G73						RESERVED
P-G74						RESERVED
P-G75						RESERVED
P-G76						RESERVED
P-G77						RESERVED
P-G78						RESERVED
P-G79						RESERVED
P-G80						RESERVED
P-G81						RESERVED
P-G82						RESERVED
P-G83						RESERVED
P-G84						RESERVED
P-G85						RESERVED
P-G86						RESERVED
<b>P-QUI</b>					Relevance Prejudicial (MIL re: Irrelevant Marketing)	06/11/2004. Email string between AstraZeneca personnel forwarding a voicemail script regarding KOL (Key Opinion Leader) Diabetes Clarification. (AZSER2825040)



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant  Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1	McKenna DX 1					1/00/2004. U.S. Label for Serquel. (AZSER07383771-AZSER07383808)
D-2	Geller D 2, Reinstein 48					9/00/1997. Initial U.S. Label for Serquel. (AZSER 10188112 - AZSER 10188134)
D-3	Dev DX 3					1/00/2001. U.S. Label for Serquel. (AZSER07409288 - AZSER07409312)
D-4						6/00/2005. U.S. Label for Serquel. (AZSER08791831 - AZSER08791868)
D-5						10/00/2006. U.S. Label for Serquel. (AZSER10763891 - AZSER10763935)
D-6						5/00/2007. U.S. Label for Serquel XR. (AZSER23141308 - AZSER23141336)
D-7	Warner 14, Hirschfeld 17, Mullen 35, Macfadden 18, Schwartz 32, Geller 3, Arnold 14					7/00/2007. U.S. Label for Serquel. (D339-L00665059)
D-8						8/00/2007. U.S. Label for Serquel XR. (D339-L00762068)
D-9						2/00/2008. U.S. Label for Serquel XR. (D339-L01122944)
D-10	Mullen 36, Jackson 40					Serquel PDRs 1997 - Present
D-11	Arnold 38					10/00/2008. U.S. Label for Serquel XR
D-12						5/00/2008. U.S. Label for Serquel
D-13						RESERVED
D-14						RESERVED
D-15						RESERVED



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff X Defendant \_\_\_\_\_ Joint \_\_\_\_\_ Court \_\_\_\_\_  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-16					Authenticity; Foundation; Hearsay; Hearsay within hearsay	6/13/1997. Medical Officer Review. (AZSER23238814 - AZSER23238985)
D-17					Authenticity; Foundation; Hearsay; Hearsay within hearsay	8/19/1997. Medical Officer Review. (AZSER01771986 - AZSER01771992)
D-18					Authenticity; Foundation; Hearsay; Hearsay within hearsay	8/21/1997. Recommendation for Approval of Seroquel. (AZSER23238728 - AZSER23238730)
D-19					Authenticity; Foundation; Hearsay; Hearsay within hearsay	9/24/1997. Recommendation for Approval of Seroquel. (AZSER01771975 - AZSER01771977)
D-20						12/17/1999. FDA Review of Atypical Anti-Psychotics re New-onset Diabetes Mellitus. (FDACDER 003795 - FDACDER 003808) (J-28)
D-21					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	1/26/2001. Medical Officer Review of 8/31/2000 Submission by AZ. (FDACDER 001605 - FDACDER 001612)
D-22					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	5/17/2001. "Review and Evaluation of Clinical Data." (FDACDER 001627 - FDACDER 001641)
D-23					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	5/22/2001. "Review and Evaluation of Clinical Data." (FDACDER 001613 - FDACDER 001626)
D-24					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	6/25/2003. FDA Literature Update re Diabetes and Atypical Anti-psychotics. (FDACDER 001458 - FDACDER 001476)
D-25					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	10/16/2003. Medical Officer Review of sNDA for Bipolar Mania by Robert Levin. (FDACDER 000614 - FDACDER000700)
D-26					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	10/24/2003. Recommendation for Approvable Action for Seroquel for Bipolar Mania. (FDACDER000833 - FDACDER000844)



**JOINT TRIAL EXHIBIT LIST**

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-27					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	11/6/2003. Medical Officer Review by Dr. Gerard Boehm. (FDACDER 001357 - FDACDER 001362)
D-28					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	12/2/2003. Medical Officer Review by Dr. Robert Levin of AZ's Response to 10/27/03 Approvable Letter. (FDACER000701 - FDACER000706)
D-29					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	1/8/2004. Recommendation for Approval Action for Seroquel for the Treatment of Manic or Mixed Episodes in Bipolar Disorder by Thomas Laughren. (FDACDER000830 - FDACDER000832)
D-30					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	1/26/2004. Raccosin E-mail re ADA Paper. (FDACDER003833 - FDACDER003834)
D-31	Patterson DX 31				Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	5/18/2004. Approval Recommendation by Dr. Thomas Laughren in Support of the Addition of Results for a Secondary Endpoint to Labeling (12 Week Data for Acute Mania Studies.) (FDACDER001717 - FDACDER001719)
D-32					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	5/1/2006. Medical Officer Review by Dr. Gerard Boehm re Clinical Data on Atypical Antipsychotics and Diabetes. (FDACDER 001550 - FDACDER 001563)
D-33					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	9/25/2006. Medical Officer Review by Dr. Jin Zhang. (FDACDER 000877 - FDACDER 000949)
D-34					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	10/19/2006. Approval Recommendation by Dr. Thomas Laughren for Short-Term Treatment of Depressive Episodes Associated with Bipolar I Disorder. (FDACDER001089 - FDACDER001095)
D-35					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	4/5/2007. E-mail from T. Laughren to C. Rice, Responding to Request from News Reporter S. Morphet About Seroquel's Warning. (FDACDER002182 - FDACDER002183)



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff X Defendant \_\_\_\_\_ Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-36					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	4/9/2007. Medical Officer Review by Chuen re XR for Schizophrenia. (FDACDIER002018 - FDACDIER002147)
D-37					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	5/6/2008. Medical Officer Review by Levin re Maintenance of Bipolar. (FDA Website)
D-38						03/13/09. AZ Briefing Document for the April 8, 2009 Psychopharmacologic Drugs Advisory Committee (PDAC) re MDD and GAD.
D-39					Hearsay. Hearsay within Hearsay. Requirement of Authentication.	April 8, 2009. Psychopharmacologic Drugs Advisory Committee Meeting Materials
D-40	Fors 31, Geller DX 40, McKenna DX 40, Limp 29, Limp DX 40, Dev 3, Goldstein DX 40 (under 6970736-37) Nasrallah DX 5, Patterson Det. 40, Arnold DX 40					5/1/2000. FDA Request for Data re Diabetes Mellitus and Related Events. (AZ/SER6970706 - AZ/SER6970707)
D-41						6/20/2000. Meeting Minutes from 6/16/2000 Teleconference re Response to FDA Glucose Request. (AZ/SER3810268 - AZ/SER3810270)



## JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-42	Geller DX 42, Limp 28, McKenna DX 42					8/31/2000. AZ response to FDA's May 1, 2000 Request for Hyperglycemia Safety Information. (AZSER19781451 - AZSER19781538)
D-43						11/22/1988. Letter Approving Original IND Application. (AZSER00002255 - AZSER00002262)
D-44						11/24/1992. End of Phase II Conference Background Document. (AZSER00002510 - AZSER00002762)
D-45						2/22/1993. Letter from AZ to FDA re Phase III Clinical Program. (AZSER00002775 - AZSER00002784)
D-46	Goldstein DX 46					5/28/1993. Minutes of End of Phase II Meeting on 2/8/1993. (AZSER00002933 - AZSER00002939)
D-47						6/21/1993. Letter from AZ to FDA re 2/8/1993 End of Phase II Meeting. (AZSER00002940 - AZSER00003177)
D-48						7/20/1993. Comprehensive Review of Phase II Data. (AZSER00003318 - AZSER00003359)
D-49						8/24/1993. End-of-Phase II Background Document Cover Letter. (AZSER00003360 - AZSER00003364)
D-50						4/11/1994. Letter from FDA to AZ re 11/24/1992 End-of-Phase II Conference Background Document. (AZSER00003389 - AZSER00003390)
D-51						5/15/1995. Background Document for 6/26/1995 pre-NIDA Meeting. (AZSER00003719 - AZSER00004186)
D-52						7/9/1996. FDA Telephone Contact Memo re: Borison Re-analysis. (AZSER10625325 - AZSER10625326)
D-53						6/21/1995. Letter from AZ to FDA re Additional Information for pre-NIDA Meeting. (AZSER00004208 - AZSER00004209)



**JOINT TRIAL EXHIBIT LIST**

Government          Plaintiff          Defendant          X Joint          Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-54						6/23/1995. Executive Summary of 06/20/1995 pre-NDA Meeting. (AZSER00004217 - AZSER00004222)
D-55	Goldstein DX 55					6/30/1995. Summary of 6/26/1995 pre-NDA Meeting. (AZSER00004283 - AZSER00004290)
D-56						7/28/1997. Approvable Letter and Draft Labeling (AZSER00287766 - AZSER00287798)
D-57						7/31/1997. Correspondence Between AZ and FDA re Draft Labeling. (AZSER00287799 - AZSER00287884)
D-58						9/25/2000. Letter from FDA to AZ re Narrowing of Indication to Treatment of Schizophrenia. (AZSER00291411 - AZSER00291412)
D-59						2/28/2001. AZ Response to FDA's 9/25/2000 Request to Narrow the Labeled Indication to Schizophrenia. (AZSER00398330 - AZSER00398361)
D-60						4/18/2002. FDA Meeting Minutes re Serquel in Bipolar Disorder. (AZSER0562912 - AZSER0562920)
D-61						6/20/2002. Pre-NDA Meeting re: Serquel (Sustained Release). (AZSER0531105 - AZSER0531127)
D-62	Limp DX 62 (under AZSER00568051-53). Patterson DX 62					9/11/2003. Letter from FDA to AZ Requesting Addition of a Hypoglycemia and Diabetes Warning to US Label. (AZSER00568051 - AZSER00568053)
D-63	McKenna DX 63					10/15/2003. Letter from AZ to FDA Acknowledging FDA's 9/11/03 Request for Class Warning. (AZSER05316807 - AZSER05316808) (J-1)
D-64					Hearsay. Relevance; waste of time; jury confusion.	05/12/2009. AZ Briefing Document for Psychopharmacologic Drugs Advisory Committee Meeting of June 9 and 10, 2009 re Pediatric Patients with Schizophrenia and Bipolar Mania.



JOINT TRIAL EXHIBIT LIST

Government          Plaintiff   X   Defendant   X   Joint          Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-65						10/27/2003. Approvable Letter for Bipolar Mania. (AZSER00300653 - AZSER00300692)
D-66						11/11/2003. AZ Response to Approvable Letter (AZSER00450689 - AZSER00451209)
D-67						11/19/2003. Dr. Ronald Leong Presentation re: Serquel, Hypoglycemia, and Diabetes. (S339-E00955002; S339-E00955003)
D-68					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	11/21/2003. FDA Presentation at ADA/APA Consensus Meeting. (FDACDER 003809 - FDACDER 003832)
D-69	Limp 9, Limp 69					12/5/2003. Notes of Teleconference between AZ and FDA re: Proposed Class Warning re DM. (AZSER08789738 - AZSER08789739) (J-24)
D-70						12/18/2003. Letter from AZ to FDA with Labeling Supplement Submission re Class Warning Based on FDA's 9/11/2003 Letter. (AZSER00451210 - AZSER00451295)
D-71						12/18/2003. Email from AZ to FDA re Draft "Dear HCP Letter." (SQLED00539718)
D-72						8/00/2004. FDA Letter in Diabetes Care re Consensus Statement. (Diabetes Care, Vol. 27, No. 8, August 2004 pp. 2088-89)
D-73						2/19/2004. Briefing Document to FDA re Possible Indication for Serquel as Monotherapy Treatment of Depressive Episodes in Bipolar Disorder. (D339-L01020320; D339-L01020321)
D-74						2/24/2004. FDA Response to AZ Briefing Document re Possible Indication for Serquel Bipolar Depression. (AZ/SER1089975 - AZ/SER1089977)
D-75					Relevance: prejudicial	6/7/2004. Serquel SR Briefing Document submitted to FDA: Clinical Development Program to Support U.S. Registration of SEROQUEL® SR in the Treatment of Schizophrenia. (AZ/SER18132414 - AZ/SER18132721)



## JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-76						7/9/2004. AZ Response to FDA's 04/08/2004 Request re Metabolic Issues. (SQIED01905915)
D-77						2/3/2005. Meeting Minutes Submission from 1/14/2005 pre-sNDA Meeting with FDA Regarding Immediate and Sustained Release Trials for Bipolar Depression. (SQIED00020479)
D-78						4/13/2005. Briefing Document: Clinical Development Program to Support the Addition of Major Depressive Disorder and General Anxiety Disorder Indications to the Serquel SR Prescribing Information. (AZSER08789952 - AZSER08790265)
D-79					Hearsay	5/27/2005. Meeting Minutes of 5/13/2005 meeting with FDA re: end of Phase II for Serquel SR for MDD and GAD indications. (AZ/SER0917538 - AZ/SER0917547)
D-80					Authenticity; Foundation; Hearsay; Hearsay within hearsay; not produced	9/19/1997. FDA (CDER) Approval Package for Clozaril Label Change.
D-81						11/9/2006. Minutes of End of Phase II Meeting Between AZ and the FDA. (SQIED01813686)
D-82						10/31/1990. Letter from AZ to FDA re Draft Protocol. (AZSER00012528 - AZSER00012562)
D-83						12/17/1997. Letter from Zeneca to FDA re Trial 39. (AZSER00004912 - AZSER00004922)
D-84					Hearsay; hearsay within hearsay	1/13/1998. AZ Memo re FDA Telephone Contact. (SQIED01932240)
D-85						6/22/2007. Letter from AZ to FDA with New CBI label re Trials 125/126/127. (D339-1,00665031)



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
**Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION**

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-86						12/18/08: Letter acknowledging receipt of Pediatric Changes Being Effected (CBE) Supplemental New Drug Application from Thomas Laughren. (D339-L011686)
D-87					Hearsay	6/16/2008: FDA Website Alert Notifying Healthcare Professionals that Both Conventional and Atypical Antipsychotics are Associated with an Increased Risk of Mortality in Elderly Patients Treated for Dementia-Related Psychosis. ( <a href="http://www.fda.gov/cder/drug/infosheets/HCP/antipsychotics_convencional.htm">http://www.fda.gov/cder/drug/infosheets/HCP/antipsychotics_convencional.htm</a> )
D-88						12/22/08: FDA Response re MDD Supplemental Application. (D339-L011689)
D-89						6/25/2008: FDA Response to June 2007 glucose CBEs. (D339-L01165297)
D-90	Rak 8					9/00/2008: AZ Response to 6/25/2008 FDA Response re June 2007 Glucose CBEs. (Rak Dep. Exh. 8)
D-91						01/07/09: FDA Email re NDA 20-639 SLR-048 Responses to Submission Questions. (D339-L01169082)
D-92						1/26/09: Letter to FDA re NDA 20-639/S-048 Seroquel Tablets Amendment to Pending Supplemental Application. (D339-L01169103)
D-93						3/10/09: FDA Briefing Material for April 8, 2009 Advisory Committee Meeting.
D-94						05/08/09: FDA Briefing Material for June 9-10, 2009 Advisory Committee Meeting.
D-95						03/26/2009 fda Clinical Review. Changes in Weight, Lipids, and Glucose with Quetiapine. (No Bates Numbers; Taken from FDA Website)
D-96						12/17/1997: AZ submission of summary of clinical trial 50771L/0039 and Request for Agency Input. (AZ/SE/R00004912 - AZ/SE/R00004922)



JOINT TRIAL EXHIBIT LIST

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-97						1/26/1998. Response Letter from P. Leber to G. Linn re: AZ's 12/17/1997 Submission of Clinical Trial Summary 50771L/0039 for Agency Input. (AZ/SER00004931)
D-98	Mckenna DX 98, Rak 22					1/8/2008. FDA Request for Analyses of the Serquel Clinical Development Program for Effects Upon Metabolic Parameters. (F339-E:18597455)
D-99	Rak 24					6/26/2008. AZ's Response to FDA's 1/8/2008 Request for Analyses of the Serquel Clinical Development Program for Effects Upon Metabolic Parameters. (S339-L:02199496)
D-100	Arnold DX 100, Fors 30, Goldstein DX 100, Patterson DX 100					9/26/1997. Letter from FDA to AZ Approving Serquel for Management of Manifestations of Psychotic Disorders. (AZ/SER10188109 - AZ/SER10188135) (1-2)
D-101						3/27/2001. Letter from FDA to AZ Approving Modified Label for Serquel to Change Indication to Treatment of Schizophrenia. (AZ/SER0564408 - AZ/SER0564410)
D-102	Dev DX 102					1/12/2004. Letter from FDA to AZ approving Serquel for Treatment of Acute Manic Episodes of Bipolar I Disorder. (AZ/SER1287500 - AZ/SER1287534)
D-103	Dev DX 103					10/20/2006. Letter from FDA to AZ Approving Serquel for Treatment of Major Depressive Episodes Associated with Bipolar Disorder. (D339-L:00813687)
D-104	Dev DX 104					5/17/2007. Letter from FDA to AZ Approving Serquel XR for Treatment of Schizophrenia. (D339-L:00758635)



## JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-105						11/15/2007. Letter from FDA to AZ Approving Seroquel XR for Maintenance Treatment of Schizophrenia. (D339-1,00765057)
D-106	Dev DX 106					5/13/2008. Letter from FDA to AZ Approving Seroquel for Maintenance Treatment of Bipolar I Disorder. (D339-1,01126815)
D-107					Relevance; prejudicial	10/8/2008. Letter from FDA to AZ approving Seroquel XR as Monotherapy for Bipolar Depression, Monotherapy for Bipolar Mania, and Adjunctive Therapy for Bipolar Mania. ( <a href="http://www.fda.gov/cder/foi/appletter/2008/0220475006,%20s007,%20s008ltr.pdf">http://www.fda.gov/cder/foi/appletter/2008/0220475006,%20s007,%20s008ltr.pdf</a> )
D-108					Exhibit Not provided	RESERVED
D-109					Exhibit Not provided	RESERVED
D-110						9/20/1988. Investigational New Drug Application for Seroquel. (AZSER00000004)
D-111						7/29/1996. New Drug Application for Seroquel.
D-112	Arnold 41, Brecher DX 112					9/24/1996. Revised NDA. (AZSER00305459)
D-113	Brecher 47, Leong 5					7/29/1996. Integrated Summary of Safety for NDA. (AZSER00324412)
D-114						1/2/1997. Revisions to Integrated Summary of Safety, Section 7, Serious Adverse Events. (AZSER00285255)
D-115						2/17/1997. Cover Letter to Response to Drs. Mosholder's and Laughren's 1/22/1997 Request for ISS Safety Re-analysis. (AZ/SER00285898 - AZ/SER00285899)
D-116						5/21/1996. Integrated Summary of Efficacy for NDA. (SQ1P00110976)
D-117						12/30/2002. sNDA for Treatment of Acute Episodes of Bipolar Mania. (SQ1P00382034)



**JOINT TRIAL EXHIBIT LIST**

Government          Plaintiff          Defendant          X Joint          Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-118						12/30/2005. sNDA for Depressive Episodes Associated with Bi-polar Disorder. (SQ1P01588824)
D-119						7/17/2006. NDA for Serquel XR.
D-120						6/00/2007. Clinical Summary of Safety. (SQ1E1D02348200)
D-121	McKenna DX 121					12/3/2002. Clinical Summary: Quetiapine in the Treatment of Acute Mania. (D339-L00739711)
D-122						6/14/2006. Summary of Clinical Safety: Serquel SR for the Treatment of Schizophrenia. (D339-L00703049)
D-123						1/30/2008. Summary of Clinical Safety: Quetiapine XR in the Treatment of Major Depressive Disorder. (D339-L01121025)
D-124						4/24/2008. Summary of Clinical Safety: Quetiapine XR in the Treatment of Generalized Anxiety Disorder. (D339-L01125855)
D-125	Brecher DX 125, Leong 5					6/12/2006. Study 125 (D1447C00125) CSR. (F339-00009212)
D-126						6/19/2007. Study 126 (D1447C00126) CSR. (D339-L00798013)
D-127						6/19/2007. Study 127 (D1447C00127) CSR. (F339-L00101621)
D-128						4/23/1996. Study 15 (50771L/0015) CSR. (D339-L00690961)
D-129						PRINCESS Study (D1444C00004) CSR. D339-L01035134
D-130						3/24/2008. GAD Titanium Study (D1448C00009) CSR. (D339-L01123226)
D-131						3/24/2008. GAD Gold Study (D1448C00010) CSR. (D339-L01124065)
D-132						3/17/2007. GAD Silver Study (D1448C00011) CSR. (D339-L01122838)



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-133						4/9/2008. GAD Platinum Study (D1448C00012) CSR. (D339-1.01124830)
D-134						GAD Chromium Study CSR
D-135						12/1/2005. Study 135 (D1447C00135) CSR and Protocol. (D339-1.01030062)
D-136						11/21/2007. MDD Moonstone Study (D1448C00001) CSR. (D339-1.01122417)
D-137						12/5/2007. MDD Diamond Study (D1448C00002) CSR. (D339-1.01122418)
D-138						1/17/2008. MDD Opal Study (D1448C00003) CSR. (D339-1.01122419)
D-139						11/20/2007 MDD Amber Study (D1448C00004) CSR. (D339-1.01122420)
D-140						1/29/2008. MDD Amethyst Study (D1448C00005) CSR. (D339-1.01122421)
D-141						3/2/2006. Study 41 (50771L/0041) CSR. (D339-1.00718237)
D-142	Brecher DX 142					3/11/2002. Study 41 (50771L/0041) Amended protocol and summary of changes sent to FDA. (SQ1P00562830)
D-143						10/13/2005. Study 43 (5077US/0043) CSR. (D339-1.00677159)
D-144	Geller DX 144					3/23/2001. Study 43 (5077US/0043) Study Protocol and Amendments. (D339-1.00677159)
D-145						4/1/2008. Study 144 (D1447C00144) CSR. (D339-1.01124072)
D-146						9/27/2005. Study 46 (5077US0046) CSR. (D339-1.00677146)
D-147						12/10/2007. MDD Pearl Study (D1448C00006) CSR. (D339-1.01122422)



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SERROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-148						11/20/2007. MDD Onyx Study (D1448C00007) CSR. (D339-101122423)
D-149						4/22/2008. MDD Sapphire Study (D1448C00014) CSR. (D339-101125905)
D-150					Exhibit Not provided	PSUR Summary Exhibit per Fed R. Evid. 1006.
D-151						11/27/1996. Four Month Safety Update. (AZSER10866896 - AZSER10869809)
D-152						6/20/1997. Preapproval Safety Update. (AZSER10869810 - AZSER10870401)
D-153						7/25/1997. Preapproval Safety Update. (AZSER10870402 - AZSER10870416)
D-154						12/27/1997. Periodic Adverse Drug Experience Report 9/27/1997 - 12/27/1997. (AZSER00456808 - AZSER00456868)
D-155						4/27/1998. Periodic Adverse Drug Experience Report 12/28/1997 - 3/27/1998. (AZSER00456869 - AZSER00456987)
D-156						8/12/1998. PSUR 03/22/1998 - 06/27/1998. (SQ1P01119477)
D-157						10/1/1998. PSUR 02/01/1998 - 07/31/1998. (SQ1P01119717)
D-158						12/1/1998. PSUR 8/1/1998 - 10/31/1998. (SQ1P01119888)
D-159						3/4/1999. PSUR 08/01/1998 - 01/31/1999. (SQ1P01120091)
D-160						6/2/1999. PSUR 02/01/1999 - 4/30/1999. (SQ1P01120360)
D-161						9/3/1999. PSUR 02/01/1999 - 07/31/1999. (SQ1P01120561)
D-162						11/29/1999. PSUR 08/01/1999 - 10/31/1999. (SQ1P01120771)



JOINT TRIAL EXHIBIT LIST

Government          Plaintiff          Defendant          X Joint          Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-163						3/3/2000. PSUR 11/01/1999 - 01/31/2000. (SQ1P01120938)
D-164						6/7/2000. PSUR 02/01/2000 - 04/30/2000. (SQ1P01121153)
D-165						9/11/2000. PSUR 05/01/2000 - 07/31/2000. (SQ1P01121364)
D-166	Arnold DX166, Dev DX 166, Geller DX 166					9/20/2001. PSUR 08/01/2000 - 07/31/2001. (AZSER07409971)
D-167					Exhibit Not provided	10/31/1989. 1989 Annual Report for IND 32, 132 (SQ1P00256809)
D-168	Dev DX 168, Geller DX 168					9/27/2002. PSUR 08/01/2001 - 07/31/2002. (SQ1P00415213)
D-169	Dev DX 169					9/25/2003. PSUR 08/01/2002 - 07/31/2003. (AZ/SER0461764)
D-170					Exhibit Not provided	10/17/1990. 1990 Annual Report for IND 32, 132 (SQ1P00257 846)
D-171	Dev DX 171					9/27/2004. PSUR 08/01/2003 - 07/31/2004. (AZ/SER0463706)
D-172	Dev DX 172					9/19/2005. PSUR 08/01/2004 - 07/31/2005. (AZ/SER0480445)
D-173						10/4/2006. PSUR 08/1/2005 - 07/31/2006. (SQ1P02453609)
D-174						9/17/2007. PSUR 08/1/2006 - 07/31/2007. (D339-L01041775)
D-175						9/15/2008. PSUR 08/01/2007 - 07/31/2008. (D339-L01166339)
D-176					Exhibit Not provided	12/10/1991. 1991 Annual Report for IND 32, 132 (SQ1P00258369)



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff  Defendant  Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
**Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION**

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-177					Exhibit Not provided	12/22/1992. 1992 Annual Report for IND 32, 132 (SQ1P00258797)
D-178					Exhibit Not provided	11/16/1993. 1993 Annual Report for IND 32, 132 (SQ1P00260326)
D-179					Exhibit Not provided	09/27/1994. 1994 Annual Report for IND 32, 132 (SQ1P00261246)
D-180					Exhibit Not provided	10/02/1995. 1995 Annual Report for IND 32, 132 (SQ1P00261349)
D-181					Exhibit Not provided	09/20/1996. 1996 Annual Report for IND 32, 132 (SQ1P00261509)
D-182					Exhibit Not provided	08/20/1999. 1999 Annual Report for IND 32, 132 (SQ1P0272731)
D-183					Exhibit Not provided	03/09/2001. 2000 Annual Report for IND 32, 132 (SQ1P00262562)
D-184					Exhibit Not provided	10/31/20012001. Annual Report for IND 32, 132 (SQ1P00262632)
D-185					Exhibit Not provided	11/21/2001. 2001 Annual Report for NDA 20-639 (SQ1P00436338)
D-186					Exhibit Not provided	11/18/2002. 2002 Annual Report for NDA 20-639 (SQ1P00436667)
D-187					Exhibit Not provided	11/04/2002. 2002 Annual Report for IND 32, 1332 (SQ1P00262686)
D-188					Exhibit Not provided	11/19/2003. 2003 Annual Report for IND 32, 132 (SQ1P00263040)
D-189					Exhibit Not provided	11/24/2003. 2003 Annual Report for NDA 60-639 (SQ1P00437164)
D-190					Exhibit Not provided	11/17/2004. 2004 Annual Report for IND 32, 132 (SQ1P00263134)
D-191					Exhibit Not provided	11/15/2004. 2004 Annual Report for NDA 20-639 (SQ1P00438069)
D-192					Exhibit Not provided	11/01/2005. 2005 Annual Report for IND 32, 132 (SQ1P00872338)



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff  Defendant  Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-193					Exhibit Not provided	11/17/2005. 2005 Annual Report for NIDA 20-639 (SQIP01587836)
D-194					Exhibit Not provided	11/15/2006. 2006 Annual Report for NIDA 20-639 (D339-101034850)
D-195					Exhibit Not provided	11/20/2006. 2006 Annual Report for IND 32. 132 (D339-1,00672655)
D-196					Exhibit Not provided	11/15/2007. 2007 Annual Report for NIDA 20-639 (D339-1,00813573)
D-197					Exhibit Not provided	11/20/2007. 2007 Annual Report for IND 32. 132 (D339-1,00844800)
D-198						9/19/1997. IND Annual Progress Report Submitted to FDA. (AZSER00138283)
D-199						9/21/1998. IND Annual Progress Report Submitted to FDA. (AZSER00138793)
D-200	Geller D 200					6/2/2000. SERM Draft Discussion Document re Diabetes Mellitus & Weight Gain (and transmitting email). (AZSER12857840 - AZSER12857849)
D-201	Geller DX 201					6/5/2000. SERM Draft Discussion Document re Diabetes Mellitus. (AZSER12873632 - AZSER12857642)
D-202	Geller DX 202					6/9/2000. SERM Draft Discussion Document re Diabetes Mellitus. (AZSER12858844 - AZSER12858854)
D-203	Geller 21, Geller DX 203, 1 imp 33, Dev DX 203					6/22/2000. SERM Discussion Document re Diabetes Mellitus. (AZSER07402905 - AZSER07402921)
D-204	Arnold DX 204, Dev DX 204, Geller DX 204					6/22/2000. SERM Minutes. (AZSER06777541 - AZSER06777547)
D-205						RESERVED



**JOINT TRIAL EXHIBIT LIST**

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-206	Brecher DX 206 Geller DX 206					11/14/2000. SERM Discussion Document re Diabetes Mellitus. (AZSER09669108 - AZSER09669159)
D-207	Dev DX 207, Geller DX 207					11/14/2000. SERM Minutes. (AZSER15727462 - AZSER15727465)
D-208						12/00/2000. SERM Safety Position Paper re Diabetes Mellitus. (AZSER10480434 - AZSER10480455)
D-209						12/16/2002. SERM Discussion Document re Glucose Dysregulation. (D339-1.00743801)
D-210						12/17/2002. SERM Minutes. (AZSER10415506 - AZSER10415507) (J-27)
D-211						RESERVED
D-212	Leong DX 212					7/10/2003. SERM Discussion Document re Glucose Dysregulation. (AZSER18317154 - AZSER18317232)
D-213						7/10/2003. SERM Minutes. (AZSER10415508 - AZSER10415510)
D-214	Warner 42, Warner DX 214					7/24/2003. SERM Safety Position Paper re Glucose Dysregulation. (AZSER18317070 - AZSER18317153)
D-215	Arnold DX 215					2/19/2004. SERM Discussion Document re Glucose Dysregulation. (AZSER10478763 - AZSER10478876) (J-25)
D-216	Arnold 12					2/19/2004. SERM Minutes. (AZSER10415511) (J-3)
D-217	Warner 41					4/12/2004. SERM Safety Position Paper re Glucose Dysregulation. (D339-1.00743816)
D-218						6/1/2006. SERM Discussion Document re Glucose Dysregulation. (D339-1.00743984)
D-219						8/21/2006. SERM Minutes. (SQLEDD02588107)



**JOINT TRIAL EXHIBIT LIST**

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-220						6/1/2006. SERM Safety Position Paper re Glucose Dysregulation. (D339-L00743934)
D-221	McKenna 17, Limp 23, Patterson DX 221					6/00/2007. SERM Discussion Document re Glucose Dysregulation. (AZSER14868252 - AZSER14868839)
D-222						6/00/2007. Addendum to SERM June 2007 SERM Discussion Document re Glucose Dysregulation. (D339-L00744119)
D-223	Arnold 9, Limp 21, McKenna 11, Rak 19, Warner 11					6/8/2007. SERM Minutes. (AZSER23260840 - AZSER23260841) (J-4)
D-224						6/15/2007. Clinical Overview re Glucose Dysregulation. (D339-L00744030)
D-225						RESERVED
D-226						RESERVED
D-227						RESERVED
D-228						RESERVED
D-229						RESERVED
D-230						SERM Summary Exhibit per Fed. R. Evid. 1006.
D-231						6/22/2000. SERM Discussion Document re Weight Gain. (AZSER10480138 - AZSER10480150)
D-232	Brecher 31, Zook 9 (under AZ/SER 6951509-17)					4/5/2001. SERM Justification Document re Weight Gain. (AZSER06773568 - AZSER06773577) (J-5)



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-233						6/1/2001. SERM Discussion Document re Weight Gain. (AZ/SER 6631049 - AZ/SER 6631066)
D-234						7/30/2001. SERM Minutes. (AZ/SER10415489 - AZ/SER10415491)
D-235						2/12/2002. SERM Discussion Document re Weight Gain. (AZ/SER10478747 - AZ/SER10478762)
D-236						2/12/2002. SERM Minutes. (AZ/SER10684297)
D-237	Gaskill 53					7/15/2002. SERM Justification Document re Weight Gain. (AZ/SER10480425 - AZ/SER10480433) (1-22)
D-238						12/16/2002. Justification Document Seroquel: Frequencies of Adverse Drug Reactions for Seroquel. (AZ/SER07409153 - AZ/SER07409158)
D-239	Rak 9					7/00/2008. SERM Discussion Document: SEROQUEL/SEROQUEL XR and Weight Gain. (Rak Dep. Exh. 9)
D-240	Rak 18					7/9/2008. SERM Minutes. (Rak Dep. Exh. 18) (S339-L02200182)
D-241	Rak 7					7/00/2008. SERM Clinical Overview on Weight Gain. (Rak Dep. Exh. 7)
D-242	Rak 16					7/00/2008. SERM Clinical Overview on Weight Gain in Pediatric Patients. (Rak Dep. Exh. 16) (S339-1.02419616-E006)
D-243						RESERVED
D-244						RESERVED
D-245						RESERVED
D-246						RESERVED
D-247						RESERVED
D-248						RESERVED
D-249						RESERVED



**JOINT TRIAL EXHIBIT LIST**

\_\_\_ Government \_\_\_ Plaintiff \_\_\_ Defendant \_\_\_ X \_\_\_ Joint \_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-250					Exhibit Not provided	RESERVED
D-251					Exhibit Not provided	RESERVED
D-252					Exhibit Not provided	RESERVED
D-253					Exhibit Not provided	RESERVED
D-254					Exhibit Not provided	RESERVED
D-255						4/15/2004, Guidelines re: Diabetes for Seroquel Protocols (SQIED00109307; SQIED00109308)
D-256					Exhibit Not provided	RESERVED
D-257						6/30/2000, SERM SOP (SOP 7, Ver. 1) (AZSER23338287 - AZSER23338304)
D-258						2/1/2002, SERM SOP (SOP 7, Ver. 2) (AZSER07407483 - AZSER07407498)
D-259						11/1/2003, SERM SOP (SOP 7, Ver. 3) (AZSER10790981 - AZSER10790997)
D-260						7/1/2005, SERM SOP (SOP-332-G, Ver. 2) (AZSER10790966 - AZSER10790980)
D-261					Exhibit Not provided	RESERVED
D-262						10/1/2003, Handling of Investigator-Sponsored Studies (SOP 21 Ver. 1), (SQIED00238185)
D-263					Exhibit Not provided	RESERVED
D-264					Exhibit Not provided	RESERVED
D-265					Exhibit Not provided	RESERVED
D-266					Exhibit Not provided	RESERVED
D-267					Exhibit Not provided	RESERVED
D-268					Exhibit Not provided	RESERVED
D-269					Exhibit Not provided	RESERVED
D-270					Exhibit Not provided	RESERVED
D-271					Exhibit Not provided	RESERVED
D-272					Exhibit Not provided	RESERVED
D-273					Exhibit Not provided	RESERVED
D-274					Hearsay	10/27/1994, ICH Guidelines re: Recommended Exposure in NDA.



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-275	Arnold DX 275, Dev DX 275, Geller DX 275					Seroquel Safety Surveillance Plan. (AZSER10415456 - AZSER10415477)
D-276						2/00/1998. Seroquel Pharmacovigilance Plan. (S339-1:00956481)
D-277	Dev DX 277, Lecong DX 277					10/10/2003. Seroquel Safety Surveillance Plan. (AZ/SER7298068-AZ/SER7298084)
D-278					Exhibit Not provided	RESERVED
D-279					Exhibit Not provided	RESERVED
D-280						7/18/05. FDA. Adverse Event Reporting System (AERS): Office of Pharmacoeptomiology and Statistical Science: Brief Description with Caveats of System (AZ/DE 0000553 - AZ/DE: 0000560)
D-281					Exhibit Not provided	RESERVED
D-282					Exhibit Not provided	RESERVED
D-283					Exhibit Not provided	RESERVED
D-284					Exhibit Not provided	RESERVED
D-285					Exhibit Not provided	RESERVED
D-286					Exhibit Not provided	RESERVED
D-287					Exhibit Not provided	RESERVED
D-288					Exhibit Not provided	RESERVED
D-289					Exhibit Not provided	RESERVED
D-290					Exhibit Not provided	RESERVED
D-291					Exhibit Not provided	RESERVED
D-292					Exhibit Not provided	RESERVED
D-293					Exhibit Not provided	RESERVED
D-294					Exhibit Not provided	RESERVED



## JOINT TRIAL EXHIBIT LIST

\_\_\_\_ Government \_\_\_\_ Plaintiff \_\_\_\_ Defendant \_\_\_\_ X Joint \_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-295					Authenticity; Relevance; Foundation; Hearsay; Hearsay within hearsay; not previously produced	Clozapine PDR
D-296					Authenticity; Relevance; Foundation; Hearsay; Hearsay within hearsay; not previously produced	Zyprexa PDR
D-297					Authenticity; Relevance; Foundation; Hearsay; Hearsay within hearsay; not previously produced	Risperdal PDR
D-298					Authenticity; Relevance; Foundation; Hearsay; Hearsay within hearsay; not previously produced	Geodon PDR
D-299					Authenticity; Relevance; Foundation; Hearsay; Hearsay within hearsay; not previously produced	Abilify PDR
D-300						12/30/2003. E-mail from FDA to AZ with Proposed Edits to Draft "Dear Healthcare Provider" Letter re: Diabetes Language. (AZSER00300917 - AZSER00300919)
D-301						12/3/2003. E-mail from Doris Bates of FDA Attaching Counterproposed Labeling. (SQIED00050680; SQIED00050682)
D-302	Gaskill 21, MacFadden 4, Linn 13					1/30/2004. "Dear HCP Letter" re: Hypertglycemia and Diabetes Related Warnings. (AZSER00301223 - AZSER00301226)
D-303						4/8/2004. E-mail from Boorstein (AZ) to Hardeman (FDA) re Dear HCP Letter. (AZ/SFR00301263 - AZ/SFR00301263)



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant  Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-304	MacFadden 5, Jackson 55, Limp 304					4/22/2004. Revised "Dear HCP Letter." (AZSER10376375 - AZSER10376377) (J-23)
D-305						4/27/2004. AZ letter to FDA re revised "Dear HCP Letter." (AZSER00301343 - AZSER00301344)
D-306						7/1/2005. AZ letter to FDA re "Dear HCP Letter" Concerning Additional Warning for Mortality Risk in Elderly Patients with Dementia. (AZSER11013548 - AZSER11013553)
D-307						RESERVED
D-308						RESERVED
D-309						RESERVED
D-310	Brecher DX 310, Dev DX 310, Geller DX 310				Hearsay; hearsay within hearsay	6/24/2002. Executive Summary of Meeting re: Glucose data with Drs. Goldstein and Woolf. (AZ/SER6625345 - AZ/SER6625346)
D-311					Hearsay; hearsay within hearsay	1/23/2006. Executive Summary of Teleconference with External Experts on Trial 125 Results. (AZSER06495894)
D-312						10/2/2002. E-mail from Martin Jones re: glucose results from Study 41. (AZSER07408304 - AZSER07408364)
D-313						RESERVED
D-314						RESERVED
D-315						RESERVED
D-316						RESERVED
D-317						RESERVED
D-318						RESERVED
D-319						RESERVED
D-320						RESERVED



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-321						4/29/09. Poster, Extended release quetiapine fumarate (quetiapine XR) monotherapy for major depressive disorder (MDD): a double-blind, placebo-controlled study; Adjunctive extended-release quetiapine fumarate (quetiapine XR) in patients with major depressive disorder.
D-322					Plaintiff has been denied an opportunity to meaningfully object because AstraZeneca failed to provide Plaintiff with an electronic image. AstraZeneca's Supplemental Exhibit is a corrupt file.	2/14/08. A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Immediate-release Tablets in Daily Doses of 400 mg and 800 mg Compared with Placebo in the Treatment of Adolescents with Schizophrenia (D1441C00112 - 5077IL/0112)
D-323					Relevance. Prejudice outweighs probative value; waste of time; jury confusion; Hearsay. Requirement of Authentication.	9/6/07. A 3-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Immediate-release Tablets in Daily Doses of 400 mg and 600 mg Compared with Placebo in the Treatment of Children and Adolescents with Bipolar I Mania (D1441C00149)
D-324					Relevance. Prejudice outweighs probative value; waste of time; jury confusion; Hearsay. Requirement of Authentication.	7/10/08. A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL) Immediate-release Tablets in Daily Doses of 400 mg and 800 mg in Children and Adolescents with Bipolar I Disorder and Adolescents with Schizophrenia (D1441C00150)
D-325	Geller 41, Lecong DX 1					8/8/2002. E-mail Chain Between W. Geller and B. Arnold re: Possible Signal of DM. (SQIED00460189)
D-326	Geller 16					10/23/2000. E-mail from W. Geller re: Document sent to Dutch Regulators. (SQIED00428635)



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-327					Exhibit Not provided	05/02/00. E-mail from Turnas to Murray, et al. re Shultz meta analysis. (SQ2FED00362242-0001) (SQ2FED00362242-0001)
D-328						6/1/2001. E-mail from W. Geller re: Delaying Implementation of Change to CDS. (SQ1HED00430833)
D-329					Exhibit Not provided	08/17/2005. Minutes re PRB DC Meeting on Serquel MDD GAID. (SQ1HED00012091-0001 - SQ1HED00012091-00009)
D-330	Brecher DX 330					7/30/2002. E-mail from W. McFadden re: Collection of Fasting Glucose Samples in Trial 49. (AZ/SER 6968575 - AZ/SER 6968576)
D-331						8/25/2003. Memo from R. Leong and L. Warner re: July 10 SERM Meeting. (AZ/SER09583218)
D-332	Scott 1070					10/15/07. Study 151 [D1447C00001] CSR (AZSER 026436260 - AZSER 026440519)
D-333	Scott 1054					11/13/07. Study 2 [D144CC00002] CSR (D339-1J01050706-00001 - D339-1J01050706-01004)
D-334	Scott 1055					4/17/96. Study 4 [5077IL/0004] CSR (AZSER 000166610 - AZSER 000166970)
D-335	Dev DX 335					5/4/2005. Serquel Safety Review Agenda and Presentations. (SQ1E000570576; SQ1E000570578)
D-336	Scott 1056					11/20/07. Study 4 [D144CC00004] CSR (AZSER 020720876 - AZSER 020721943)
D-337	Scott 1057					6/4/95. Study 6 [5077IL/0006] CSR (AZSER 000180993 - AZSER 000181354)
D-338	Scott 1058					8/22/95. Study 8 [5077IL/0008] CSR (AZSER 000166234 - AZSER 000166609)
D-339	Scott 1059					9/8/06. Study 39 [5077IL-0039] CSR (AZSER 017174756 - AZSER 017182307)



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant  Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-340	Scott 1060					7/20/05. Study 49 [5077US-0049] (BOLDER I) CSR (AZSER 018146493 - AZSER 018154517)
D-341	Scott 1061					12/2/02. Study 99 [5077IL-0099] CSR (AZSER 017324870 - AZSER 017328196)
D-342	Scott 1062					11/29/02. Study 100 [5077IL-0100] CSR (AZSER 018621826 - AZSER 018624398)
D-343	Scott 1063					12/3/02. Study 104 [5077IL-0104] CSR (AZSER 018155041 - AZSER 018164811)
D-344	Scott 1064					12/10/02. Study 105 [5077IL/0105] CSR (AZSER 018184891 - AZSER 018195533)
D-345	Scott 1596					2/14/08. Study 112 - A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate Immediate-release Tablets in Daily Doses of 400 mg and 800 mg Compared with Placebo in the Treatment of Adolescents with Schizophrenia
D-346	Scott 1597. Zook DX 346				Relevance. Prejudice outweighs probative value; waste of time; jury confusion. Hearsay. Requirement of Authentication.	9/6/07. Study 149 - A 3-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebocontrolled.; Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate Immediate-release Tablets in Daily Doses of 400 mg and 600 mg Compared with Placebo in the Treatment of Children and Adolescents with Bipolar I Mania
D-347	Scott 1067					5/8/06. Study 132 [D1444C00132] CSR (AZSER 016833770 - AZSER 016843171)
D-348	Scott 1068					5/29/06. Study 133 [D1444C00133] CSR (D339-L00719457-00001 - D339-L00719457-04282)
D-349	Scott 1069					10/5/07. Study 134 [D1447C00134] CSR (D339-L00809048-00001 - D339-L00809048-02447)
D-350	Gaskill 5. Limip 55. Limip 350				Hearsay	8/28/1997. FDA Telephone Contact Memo re: Press Release Input from Dr. Leah Palmer. (AZSER03926944 - AZSER03926946)



## JOINT TRIAL EXHIBIT LIST

\_\_\_\_ Government \_\_\_\_ Plaintiff \_\_\_\_ Defendant \_\_\_\_ X Joint \_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-351	Zook DX 351					1/23/2004. Zook e-mail re OPMT feedback. (AZ/SER3791849 - AZ/SER3791850) (1-26)
D-352						Ma E-mail re Physician Specialty and Patient Base. (AZ/SER13045912)
D-353						9/17/1999. Letter from Zeneca to FDA re Elderly Ad. (AZ/SER00290496 - AZ/SER00290497)
D-354						3/31/2000. Speaker Program Guidelines. (SQIED00288713)
D-355						RESERVED
D-356						2/8/2002. AZ Policy re Engaging Health Care Professionals, Institutions, & Organizations in Contracted Services. (AZ/SER6780575 - AZ/SER6780580)
D-357						2009. FDA. Guidance for Industry. Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices U.S. Available online <a href="http://www.fda.gov/oc/op/goodreprint.html">www.fda.gov/oc/op/goodreprint.html</a>
D-358						1997. FDA Policies on Off-Label Use - Slide from Janet Woodcock Presentation - 1997 - Available on line at <a href="http://www.fda.gov/cder/present/diamondtreat/regappr">www.fda.gov/cder/present/diamondtreat/regappr</a>
D-359						4/00/1982. FDA Drug Bulletin re "Unlabeled" Uses.
D-360						1998. FDA Information Sheet re "Off-Label" Use.
D-361						3/00/2003. AZ Business Policies: Partners in Policy Binder. (AZ/SER10379588 - AZ/SER10379921)
D-362						RESERVED
D-363						RESERVED
D-364						9/00/2003. The COPE Consumer Guide: Taking Care of Yourself. (AZ/SER10460316 - AZ/SER10460346)
D-365						05/19/1999 Letter from Gerald L. Limp to Lisa L. Stockbridge, Ph.D. (AS/SER00290181-85)



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-366					Exhibit Not provided	06/21/1999 Letter from Lisa L. Stockbridge, Ph.D. to Gerald L. Limp. (D339-L00678414-0001-02)
D-367					Exhibit Not provided	RESERVED
D-368					Exhibit Not provided	01/15/2009 Letter from James L. Gaskill to Amy Toscano, with attached fax cover sheets. (No Bates number)
D-369					Exhibit Not provided	01/30/2009 Letter from Amy Toscano to James L. Gaskill, with attached fax cover sheet. (No Bates number)
D-370					Exhibit Not provided	RESERVED
D-371					Exhibit Not provided	RESERVED
D-372						9/3/2004. CNS Newsflash. (AZ/SER20903499 - AZ/SER20903502)
D-373						12/2/2004. Gaskill e-mail re "Question from S.L.T on Promotion of SEROQUEL as Adjunctive Therapy in Major Depressive Disorder." (AZ/SER3344442 - AZ/SER3344443)
D-374					Exhibit Not provided	RESERVED
D-375					Exhibit Not provided	RESERVED
D-376					Exhibit Not provided	RESERVED
D-377						5/12/2005. Instructions from Seroquel Brand Team re APA Annual Meeting. (SQHEID01237045)
D-378					Exhibit Not provided	RESERVED
D-379						RESERVED
D-380						RESERVED
D-381						RESERVED
D-382					Exhibit Not provided	RESERVED
D-383						3/8/2006. Standards for Conducting Speaker Programs. (AZ/SER1405334 - AZ/SER1405338)
D-384					Exhibit Not provided	RESERVED
D-385					Exhibit Not provided	RESERVED



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff  Defendant  Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-386						10/20/2006. Press Release: FDA Approves AstraZeneca's Serquel For Bipolar Depression Treatment. (AZSER10443817 - AZSER10443820)
D-387						6/19/2006. VM from Paulson. (AZSER10447755)
D-388						10/20/2006. VM from Paulson. (AZSER10448619)
D-389	Gaskill 4					8/18/1997. AZ Submission of Introductory Promotional Material to DDMAC for Approval. (AZSER00288068 - AZSER00288070)
D-390						3/20/2006. FDA Form 2263 for DM Fact Sheet Aid. ID # 238110. (SQIED11100921)
D-391						11/20/2006. Jackson VM re 238110. (SQIED01381369)
D-392						11/22/2006. Newsflash re 238110. (SQIED01395173)
D-393						11/29/2006. Paulson VM re 238110. (SQIED01395179)
D-394						11/29/2006. Announcement re DM Content. (AZSER10449024)
D-395						11/30/2006. Letter from AZ to DDMAC in Response to November 16, 2006 Untitled Letter. (AZSER15725503 - AZSER15725509)
D-396						1/2/2007. Letter from AZ to DDMAC in Response to December 15, 2006 Letter. (AZSER15725728 - AZSER15725729)
D-397						1/12/2007. Letter from AZ to DDMAC in Response to January 2, 2007 Letter. (AZSER15725743 - AZSER15725744)
D-398						1/18/2007. FDA Letter to AZ Closing Untitled Letter Matter. (SQIED01379720)
D-399						RESERVED



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff \_\_\_\_\_ Defendant X Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-400						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-401						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-402						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-403						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-404						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-405						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-406						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-407						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-408						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-409						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-410						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-411						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-412						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-413						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-414						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-415						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-416						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-417						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-418						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-419						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-420						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-421						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-422						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-423						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-424						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-425						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-426						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-427						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-428						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-429						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-430						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-431						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES



JOINT TRIAL EXHIBIT LIST

Government \_\_\_\_\_ Plaintiff   X   Defendant \_\_\_\_\_ Joint \_\_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-432						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-433						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-434						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-435						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-436						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-437						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-438						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-439						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-440						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-441						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-442						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-443						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-444						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-445						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-446						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-447						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-448						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-449						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-450						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-451						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-452						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-453						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-454						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-455						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-456						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-457						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-458						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-459						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-460						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-461						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-462						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-463						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES



**JOINT TRIAL EXHIBIT LIST**

Government \_\_\_\_\_ Plaintiff X Defendant \_\_\_\_\_ Joint \_\_\_\_\_ Court \_\_\_\_\_  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-464						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-465						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-466						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-467						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-468						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-469						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-470						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-471						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-472						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-473						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-474						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-475						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-476						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-477						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-478						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-479						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-480						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-481						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-482						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-483						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-484						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-485						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-486						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-487						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-488						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-489						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-490						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-491						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-492						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-493						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-494						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-495						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES



**JOINT TRIAL EXHIBIT LIST**

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-496						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-497						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-498						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-499						RESERVED FOR CASE-SPECIFIC DEMONSTRATIVES
D-500	Leong 2					American Diabetes Association, et al. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. <i>Diabetes Care</i> . 2004; 27(2): 596-601. (1-6)
D-501						Dinan, T et al. 'Schizophrenia and Diabetes 2003' Expert Consensus Meeting. Dublin, 3-4 October 2003: Consensus Summary. <i>British Journal of Psychiatry</i> . 2004; 184 (suppl. 47): s112-s114.
D-502						Adityanjee, MD et al. Clinical Use of Quetiapine in Disease States Other than Schizophrenia. <i>Journal of Clinical Psychiatry</i> . 2002; 63(suppl 13): 32-38.
D-503						AHRQ Effective Health Care Program Summary Guides. Off-Label Use of Atypical Anti-Psychotic Drugs.
D-504						Allebeck, P. Schizophrenia: A Life Shortening Disease. <i>Schizophrenia Bulletin</i> . 1999; 15(1): 81-89.
D-505						Altman, CA et al. The Effects of Long-Term Quetiapine Monotherapy on Weight in Patients with Schizophrenia. <i>Biological Psychiatry</i> . 2001; 49: 53S.
D-506						Amdisen, A. Drug-Produced Obesity: Experiences with Chlorpromazine, Perphenazine, and Clopenthixol. <i>Danish Medical Bulletin</i> . 1964; 2(6): 182-189.
D-507						American Academy of Child and Adolescent Psychiatry. Official Action: Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disease. <i>Journal of the American Academy of Child Adolescent Psychiatry</i> . 2000; 46(1): 107-125.
D-508						American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. <i>Diabetes Care</i> 2008; 31 (1): s55-s60.



**JOINT TRIAL EXHIBIT LIST**

\_\_\_\_ Government \_\_\_\_ Plaintiff \_\_\_\_ Defendant X Joint \_\_\_\_ Court  
 Case No. 6:06-cv-1769-ACC-DAB  
**Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION**

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-509						American Diabetes Association. "Screening for Type 2 Diabetes." <i>Diabetes Care</i> 2004; 27: s11-s14.
D-510						American Psychiatric Association Schizophrenia Backgrounder. APA 2007.
D-511						Arvanitis, L et al. Multiple Fixed Doses of "Seroquel" (Quetiapine) in Patients with Acute Exacerbation of Schizophrenia: A Comparison with Haloperidol and Placebo. <i>Biological Psychiatry</i> . 1997; 42: 233-246.
D-512						Atmaca, M et al. Quetiapine Is Not Associated with Increase in Prolactin Secretion in Contrast to Haloperidol. <i>Archives of Medical Research</i> 2002; 33:562-565.
D-513						Axelsson, R et al. Factors Predicting Suicide in Psychotic Patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> . 1992; 241: 259-266.
D-514						Baldessarini, R. et al. Suicide Risk and Treatment for Patients with Bipolar Disorder. <i>Journal of the American Medical Association</i> . 2003; 290 (11): 1517-1520.
D-515						Barbato, A. <i>Schizophrenia and Public Health</i> . Division of Mental Health and Prevention of Substance Abuse. World Health Organization. 1996. 1-40.
D-516						Barner, J et al. Frequency of New-Onset Diabetes Mellitus and Use of Antipsychotic Drugs Among Central Texas Veterans. <i>Pharmacotherapy</i> . 2004; 24(11): 1529-1538. (1-7)
D-517						Barnett, M et al. A Regional Comparison of Developing Diabetes among VA Patients Exposed to Typical and Atypical Antipsychotics Relative to Corticosteroids and Proton Pump Inhibitors. <i>Annals of Clinical Psychiatry</i> . 2006; 19(1): 1-7.
D-518						Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children, and Adolescents, in Primary and Secondary Care. NICE. National Clinical Practice Number 38. The British Psychological Society and Gaskell.



**JOINT TRIAL EXHIBIT LIST**

Government Plaintiff Defendant  Joint Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-519						Black, D et al. Excess Mortality Among Psychiatric Patients: The Iowa Record-Linkage Study. <i>JAMA</i> . 1985; 253: 58-61.
D-520						Black, D et al. Mortality in DSM-III-R Schizophrenia. <i>Schizophrenia Research</i> . 1992; 7:109-116.
D-521						Bobes, J et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. <i>Schizophrenia Research</i> . 2003; 62: 77-88. (1-8)
D-522						Bonoro, E et al. Population-Based Incidence Rates and Risk Factors for Type 2 Diabetes in White Individuals: The Brunek Study. <i>Diabetes</i> . 2004; 53: 1782-1789.
D-523						Bowden, C et al. A Randomized, Double-Blind, Placebo Controlled Efficacy and Safety Study of Quetiapine or Lithium as Monotherapy for Mania in Bipolar Disorder. 2005; <i>Journal of Clinical Psychiatry</i> . 2005; 66: 111-121.
D-524						Brambilla, F et al. Glucose-Insulin Metabolism in Chronic Schizophrenia. <i>Diseases of the Nervous System</i> . 1976; 37(2): 98-103.
D-525	Mullen 8					Brecher, M et al. Differential Changes in Glucose Metabolism in Patients with Schizophrenia Receiving Quetiapine, Olanzapine, or Risperidone. Abstract Poster.
D-526	Gaskill 45, Melville 20, Limp 60, Supples 10, Brecher 30, Nasrallah 4, Arnold 25, Leong 19					Brecher, M et al. The Long-Term Effect of Quetiapine (Seroquel) Monotherapy on Weight in Patients with Schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> . 2000; 4: 287-291.
D-527						Brecher M. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. <i>Journal of Clinical Psychiatry</i> . 2007; 68(4):597-603.



**JOINT TRIAL EXHIBIT LIST**

Government Plaintiff Defendant  Joint Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-528						Brown, S et al. Causes of the Excess Mortality of Schizophrenia. <i>British Journal of Psychiatry</i> . 2000; 177: 212-217.
D-529						Buse, J et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. <i>Journal of Clinical Epidemiology</i> . 2003; 56: 164-170. (1-9)
D-530						Bushne, C et al. Prevalence of Diabetes and Impaired Glucose Tolerance in Patients with Schizophrenia. <i>British Journal of Psychiatry</i> . 2004; 184(47): s67-s71.
D-531						Bushe, C et al. Blood Glucose and Schizophrenia: A Systemic Review of Prospective Randomized Clinical Trials. <i>Journal of Clinical Psychiatry</i> . 2007; 68:1682-1690.
D-532						Calabrese JR et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II Depression. <i>American Journal of Psychiatry</i> . 2005; 162:1351-1360. (1-10)
D-533						Cassidy, F. Elevated Frequency of Diabetes Mellitus in Hospitalized Manic-Depressive Patients. <i>American Journal of Psychiatry</i> . 1999; 156:1417-1420. (J-11)
D-534						Chan, J et al. Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men. <i>Diabetes Care</i> 1994; 17(9): 961-969.
D-535						Charatan, F.B.E. et al. The Effect of Chlorpromazine (Largactil) on Glucose Tolerance. <i>Journal of Mental Science</i> . 1955; 101: 351-353.
D-536	Dev 6					Cheer, S et al. Quetiapine: A Review of its Use in the Management of Schizophrenia. <i>CNS Drugs</i> 2004; 18(3): 173-199.
D-537						Chouinard, G et al. Once-Daily Extended Release Quetiapine Fumarate (QuetiapineXR) Monotherapy in Generalized Anxiety Disorder (GAD): A Phase III, Double-Blind, Placebo-Controlled Study. 2007. Abstract Poster.



JOINT TRIAL EXHIBIT LIST

Government          Plaintiff          Defendant          X          Joint          Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-538						Chouinard, G et al. Once-Daily Extended Release Quetiapine Fumarate (QuetiapineXR) Monotherapy in Generalized Anxiety Disorder (GAD): A Placebo Controlled Study with Active Comparator Patoxetine. <i>European Psychiatry</i> . 2008; 23: s211.
D-539						Citrome, J. et al. Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics. <i>Annals of Pharmacotherapy</i> . 2007; 41: 1-11.
D-540						Cohen, D et al. Hyperglycemia and Diabetes in Patients with Schizophrenia or Schizoaffective Disorders. <i>Diabetes Care</i> . 2006; 29(4): 786-791.
D-541						Colditz, G et al. Weight Gain as a Risk Factor for Clinical Diabetes in Women. <i>American Journal of Epidemiology</i> . 1990; 132(3): 501-513.
D-542						Colditz, G et al. Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women. <i>Annals of Internal Medicine</i> . 1995; 122(7): 481-486.
D-543						Collaborative Working Group on Clinical Trial Evaluations. Adverse Effects of the Atypical Antipsychotics. <i>Journal of Clinical Psychiatry</i> . 1998; 59 (12): 17-22.
D-544						Consensus Statement. Letters in Response. <i>Diabetes Care</i> . 2004; 27(8): 2086-2090.
D-545						Copolov, D et al. A Multicentre, Double-Blind, Randomized Comparison (ICI 204,636 Serquel) and Haloperidol in Schizophrenia. <i>Psychological Medicine</i> . 2000; 30: 95-105. (1-12)
D-546						Dagogo-Jack, S et al. Pathophysiology of Type 2 Diabetes and Modes of Action of Therapeutic Interventions. <i>Archives of Internal Medicine</i> . 1997; 157: 1802-1817.
D-547						Dannlowski, U et al. Adjunctive Antidepressant Treatment with Quetiapine in Agitated Depression: Positive Effects on Symptom Reduction, Psychopathology and Remission Rates. <i>Human Psychopharmacology</i> . 2008; published online: 1-7.



JOINT TRIAL EXHIBIT LIST

Government Plaintiff X Joint Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION


Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-548						Datto, C et al. Double-Blind Study of Extended Release Quetiapine Fumarate (quetiapine XR) Monotherapy for Maintenance Treatment of Major Depressive Disorder (MDD). Abstract Poster. 2008
D-549						DelBello, M et al. A Double-Blind, Randomized, Placebo-Controlled Study of Quetiapine as Adjunctive Treatment for Adolescent Mania. <i>Journal of the American Academy of Child Adolescent Psychiatry</i> . 2002; 41(10): 1216-1223.
D-550						Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. <i>NEJM</i> . 2002; 346(6): 393-403.
D-551						Dixon, L et al. Prevalence and Correlates of Diabetes in National Schizophrenia Samples. <i>Schizophrenia Bulletin</i> . 2000; 26(4): 903-912.
D-552						Doss, F. The Effect of Antipsychotic Drugs on Body Weight: A Retrospective Review. <i>Journal of Clinical Psychiatry</i> . 1979; 40: 528-530.
D-553	Birkett 52					Dossenbach, M et al. Effectiveness of Antipsychotic Treatments for Schizophrenia: Interim 6-Month Analysis From a Prospective Observational Study (IC-SOO) Comparing Olanzapine, Quetiapine, Risperidone, and Haloperidol. <i>Journal of Clinical Psychiatry</i> . 2004; 65: 312-321.
D-554						Dossenbach, M et al. Response and Relapse in Patients with Schizophrenia Treated with Olanzapine, Risperidone, Quetiapine, or Haloperidol: 12 Month Follow-Up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) Study. <i>Journal of Clinical Psychiatry</i> . 2005; 66: 1021-1030.
D-555						Eaton, W et al. Depression and Risk for Onset II Diabetes: A Prospective Population Based Study. <i>Diabetes Care</i> . 1996; 19(10): 1097-1102.
D-556						Ehrmann, D et al. Prevalence of Impaired Glucose Tolerance and Diabetes in Women with Polycystic Ovary Syndrome. <i>Diabetes Care</i> . 1999; 22(1): 141-146.



JOINT TRIAL EXHIBIT LIST

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-557						El-Khalili, N et al. Adjunctive Extended Release Quetiapine Fumarate (quetiapine XR) in patients with Major Depressive Disorder and Inadequate Antidepressant Response. Abstract Poster. 2008.
D-558	Brecher 61					Emsley, R et al. A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. <i>International Clinical Psychopharmacology</i> . 2000; 15: 121-131.
D-559						Emsley, R et al. Differential Effect of Quetiapine on Depressive Symptoms in Patients with Partially Responsive Schizophrenia. <i>Journal of Psychopharmacology</i> . 2003; 17(2): 210-215.
D-560						Emsley, R et al. A Single-Blind, Randomized Trial Comparing Quetiapine and Haloperidol in the Treatment of Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> . 2004; 65: 696-701.
D-561						Emsley, R et al. Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. <i>International Journal of Neuropsychopharmacology</i> . 2005; 14(6): 175-182.
D-562						Eliminan, M et al. Exploring the Association Between Atypical Neuroleptic Agents and Diabetes Mellitus in Older Adults. <i>Pharmacology</i> . 2003; 23(11): 1411-1415.
D-563						FDA Information Sheet: "Off Label" and Investigational Use of Marketed Drugs, Biologics, and Medical Devices. FDA Guidance for Institutional Review Boards and Clinical Investigators; 1-3.
D-564						Feldman, P et al. Retrospective Cohort Study of Diabetes Mellitus and Antipsychotic Treatment in a Geriatric Population in the United States. <i>Journal of the American Medical Directors Association</i> . 2004; 5: 38-46.
D-565						Freedman, R. Schizophrenia. <i>NEJM</i> . 2003; 349: 1738-1749.



JOINT TRIAL EXHIBIT LIST

Government  Plaintiff  Defendant  Joint  Court  
 Case No. 6:06-cv-1769-ACC-DAB  
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-566						Ganesan, S et al. Switching from Other Antipsychotics to Once-Daily Extended Release Quetiapine Fumarate in Patients with Schizophrenia. <i>Current Medical Research and Opinion</i> . 2008; 24(1): 21-32.
D-567						Geiss, L et al. Changes in Incidence of Diabetes in US Adults, 1997-2003. <i>American Journal of Preventative Medicine</i> . 2006; 30(5): 371-377.
D-568	Schwartz 57					Gianfrancesco, F et al. Antipsychotic-Induced Type 2 Diabetes: Evidence from a Large Health Plan Database. <i>Journal of Clinical Psychopharmacology</i> . 2003; 23: 328-335. (1-13)
D-569	Nasrallah 12					Gianfrancesco, F et al. The Influence of Study Design on the Results of Pharmacoeconomic Studies of Diabetes Risk With Antipsychotic Therapy. <i>Annals of Clinical Psychiatry</i> . 2006; 18(1): 9-17.
D-570						Gianfrancesco, F et al. Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: Sensitivity to study design. <i>American Journal of Health-System Pharmacists</i> . 2006; 63: 431-441.
D-571						Goodwin, F et al. Chapter 10 entitled "Suicide" from <i>Manic-Depressive Illness</i> . Oxford University Press, 1990.
D-572						Goodwin, G.M. et al. Evidence-Based Guidelines for Treating Bipolar Disorder: Recommendations from the British Association for Psychopharmacology. <i>British Journal of Psychopharmacology</i> . 2003; 17(2): 149-173.
D-573						Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia) NICE 2002; Technology Appraisal Guidance No. 43.
D-574						Gunasekara, N et al. Quetiapine: A Review of its Use in Schizophrenia. <i>CNS Drugs</i> . 1998; 9(4): 325-340.
D-575						Gupta, S et al. Hyperglycemia and Hypertiglyceridemia in Real World Patients on Antipsychotic Therapy. <i>American Journal of Therapeutics</i> . 2003; 10: 348-355. (1-14)